 
I6T-JE-AMAD (a) Protocol  
 
 A Single -Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of LY3074828 in 
Japanese and  Caucasian Healthy Subjects . 
 
[STUDY_ID_REMOVED] 
  Date: 23-Jan-2018 
 
 
I6T-JE-AMAD (a)Protoco l Page 1
LY30748281.Protocol I6T-JE-AMAD(a)
A Single -Dose Study  to Assess the Safety , Tolerability , and 
Pharmacokinetics of LY3074828 in Japanese and
Caucasian Healthy  Subjects
Confidential Information
The information contained in this protocol is confidential and is intended for the use of 
clinical investigators.  It is the property of Eli Lilly and Company or its subsidiaries and 
should not be copied by or distributed to persons not involved in the cli nical investigation of 
LY3074828 , unless such persons are bound by a confidentiality agreement with Eli Lilly 
and Company or its subsidiaries.  This document and its associated attachments are 
subject to U nited States Freedom of Information Act (FOIA) Exem ption 4.
LY3074828
Study I6T-JE-AMAD is a single -site,subject -and investigator- blind, randomized, placebo -
controlled, single -dose study to assess the safety, tolerability, and pharmacokinetics of 
LY3074828 in Japanese and Caucasian healthy subjects .  The study will consist of 
6planned dose cohorts:  5intravenous cohorts (60 mg, 200 mg, 600 mg , 1200 mg, and 
2400 mg ) and 1 subcutaneous cohort (200 mg). Subjects in each cohort will be 
randomized to receive LY3074828 or placebo.
Eli Lilly Japan K.K.
Kobe Hyogo Japan
Protocol Electronically Signed and Approved by Lilly on date provided below.
Approval Date: 23-Jan-2018 GMT
I6T-JE-AMAD (a)Protoco l Page 2
LY30748282.Synopsis
Clinical Pharmacology Protocol Synopsis:  Study I6T-JE-AMAD
Name of Investigational Product: LY3074828
Title of Study:  A Single -Dose Study  to Assess the Safety, Tolerability, and Pharmacokinetics of LY3074828 in 
Japanese and Caucasian Healthy Subjects
Number of Planned Subjects :  approximately 50subjects Phase of Development :  1
Length of Study:   approximately 16 weeks
Objectives:   The primary objective is to explore the safety and tolerability of LY3074828 in healthy Japanese and 
Caucasian subjects to define an appropriate dose for further clinical research in Japan.  The secondary objective sof 
this study are to estimate the pharmacokinetic (PK) parameters of LY3074828 following intravenous (IV) and 
subcutaneous (SC) administration in healthy Japanese and Caucasian subjects and to explore the safety, 
tolerability, and PK of LY3074828 inJapanese subjects in relation to Caucasian s ubjects .
Study Design:   Study I6T-JE-AMAD is a single -site, subject -and investigator -blind, randomized, 
placebo -controlled, single -dose study to assess the safety, tolerability, and PK of LY3074828 in Japanese and 
Caucasian healthy subjects . The study will consist of 6planned dose cohorts:  5IV cohort s (60 mg, 200 mg, 
600mg, 1200 mg, and 2400 mg ) and 1 SCcohort (200 mg).  Subjects in each cohort will be randomized to receive 
LY3074828 or placebo. Subjects will be inpatient in the clinical research unit (CRU) for treatment administration 
and will then be discharged and followed as outpatients for 12 weeks after treatment administration.
Diagnosis and Main Criteria for Inclusion and Exclusion:   This study will enroll healthy male and female
subjects who are 20 years to 64 years, inclusive, with a body mass index of 18.0 kg/m 2to 32.0 kg/m 2, inclusive, at 
screening.  Japanese subjects must be first -generation Japanese, defined as the subject, the subject’s biological 
parents ,and the subject’ s biological grandparents are all of exclusive Japanese descent and were born in Japan.
Investigational Product, Dosage, and Mode of Administration:   A single dose of LY3074828 will be 
administered IVat the planned dose levels of 60mg, 200 mg, 600 mg, 1200 mg, and 2400 mg .  A single dose of 
LY3074828 will be administered SCat a planned dose of 200mg.
Comparator, Dose, and Mode of Administration:   A single dose of placebo (sterile normal saline [0.9% sodium 
chloride ]) will be given IVorSC, as per co hort.
Planned Duration of Treatment:   LY3074828 or placebo will be given as a single dose.
Criteria for Evaluation:   
Safety :  Adverse events (AEs), serious adverse events, physical examinations, vital sign s, electrocardiograms 
(ECGs), and clinical laboratory evalu ations including immunogenicity .
Bioanaly tical:  Serum for the measurement of LY3074828 concentrations will be collected at select visits.
Pharmacokinetic :  The primary parameters for analysis will be maximum drug concentration (C max) and area under 
the concentration versus time curve (AUC) of LY3074828.  Other noncompartmental parameters, such as half -life, 
clearance ,and volume of distribution (apparent clearance and apparent volume of distribution for SC 
administration) may be repo rted.  
I6T-JE-AMAD (a)Protoco l Page 3
LY3074828Evaluation Methods:
Statistical:   Up to 60 subjects may be enrolled in order that approximately 50subjects complete the study.  It is 
intended that 10 subjects (6 Japanese and 4 Caucasian) will be randomized in Cohort 1, and 8 subjects (4 Japanese 
and 4 Caucasian) will be randomized inCohorts 2,3,4, 5, and 6.  The sample size is customary for Phase 1 studies 
evaluating safety, tolerability, and PK parameters .The first i nterim analy sis is scheduled to occur when safety and 
PK data through Day 15 become available from at least 8 subjects in Cohort 1,including at least 3Japanese 
subjects on LY3074828.  A
n additional interim analy sismay occur whensafety and PK data through Day 15 
become s available from at least 6subjects in Cohort 6, including at least 3Japanese subjects on LY3074828 . All 
safety and PK data available by this time will be included in the interim analysis .  
Safety :  Safety parameters that will be assessed include vital signs, ECG parameters ,and safety lab pa rameters.  
The parameters will be listed and summarized using standard descriptive statistics.  Additional analysis will be 
performed if warranted upon review of the data .  
Bioanaly tical:  Serum concentrations of LY3074828 will be assayed using a validate d enzyme -linked 
immunosorbent assay.
Pharmacokinetic :  PKparameter estimates for LY3074828 will be calculated by standard noncompartmental 
methods of analysis.  
I6T-JE-AMAD (a)Protoco l Page 4
LY30748283.Table of Contents
A Single -Dose Study  to Assess the Safety , Tolerability , and 
Pharmacokinetics of LY3074828 in Japanese and Caucasian 
Healthy  Subjects
Section Page
1. Protocol  I6T-JE-AMAD(a) A Single -Dose Study  to Assess the 
Safety, Tolerabili ty, and Pharmacokine tics of  LY3074828 in 
Japanese and Caucasian Healt hy Subjects ........................................................................... 1
2. Synopsis ............................................................................................................................. 2
3. Table of Contents ................................................................................................................ 4
4. Abbre viations and Definit ions........................................................................................... 10
5. Introduction ...................................................................................................................... 13
5.1. General Introduction .................................................................................................... 13
5.2. Rationale and Justificat ion for the Study ...................................................................... 16
6. Object ives......................................................................................................................... 17
6.1. Primary Object ive........................................................................................................ 17
6.2. Secondary  Object ives................................................................................................... 17
7. Invest igational Pl an........................................................................................................... 18
7.1. Summary  of Study  Design ............................................................................................ 18
7.2. Discussi on of  Design and Control ................................................................................ 20
8. Study  Popul ation............................................................................................................... 21
8.1. Criteria for Enrollment .................................................................................................21
8.1.1. Inclusio n Cri teria.................................................................................................21
8.1.2. Exclusio n Cri teria................................................................................................ 22
8.1.3. Rationale for Excl usion of Certain Study  Candidates ........................................... 24
8.2. Discontinuati on............................................................................................................ 24
8.2.1. D iscontinuation o f Subjects .................................................................................. 25
8.2.1.1. Subjects Inadvertently Enro lled...................................................................... 25
8.2.1.2. Discontinuati ons f rom Invest igational Product or from 
the Study ........................................................................................................ 25
8.2.1.3. Subjects Lost to Follow -up............................................................................. 26
8.2.2. Discontinuati on of  Study  Sites............................................................................. 26
8.2.3. Discontinuati on of  the Study ................................................................................ 26
9. Treatment .......................................................................................................................... 27
9.1. Treatment M aterials and Supplies ................................................................................. 27
9.2. Treatment Administration ............................................................................................ 27
I6T-JE-AMAD (a)Protoco l Page 5
LY30748289.3. Rationale for Sel ection of Dose .................................................................................... 28
9.4. Dose Escal ation............................................................................................................ 30
9.4.1. D ose Escal ation Method ....................................................................................... 31
9.5. Specific Restrict ions/Requirements .............................................................................. 31
9.5.1. Speci al Treatm ent Consi derat ions........................................................................ 32
9.5.1.1. Prem edicat ion for Infusio ns............................................................................ 32
9.5.1.2. Management of Infusio n Reactions .................................................................32
9.6. Blinding ....................................................................................................................... 32
9.7. Concomitant Therapy ................................................................................................... 33
10. Sample Collect ion and Safet yData Collect ion.................................................................. 34
10.1. Laboratory  Sam ples ..................................................................................................... 34
10.2. Samples for Pharm acokinetic and Pharmacodynamic Evaluat ions................................ 34
10.2.1. Pharmacokinet ic Samples ..................................................................................... 34
10.2.2. Bioanalysis ........................................................................................................... 34
10.3. Samples for Bi omarker Research .................................................................................. 35
10.3.1. Samples for Genet ic Bio marker Research ............................................................. 35
10.3.2. Samples for Expl oratory  Evaluat ion..................................................................... 35
10.4. Samples for Immunogenicit y Research ......................................................................... 36
10.5. Safety Evaluat ions........................................................................................................ 36
10.5.1. Adverse Events .................................................................................................... 36
10.5.2. Serious Adverse Events ........................................................................................ 37
10.5.2.1. Suspected Unexpected Serious Adverse React ions.......................................... 38
10.5.3. Other Safet y Measures ......................................................................................... 38
10.5.3.1. Physical Examinat ion..................................................................................... 38
10.5.3.2. Vital Signs...................................................................................................... 38
10.5.3.3. Body  Weight and Hei ght................................................................................ 39
10.5.3.4. Electrocardiograms ......................................................................................... 39
10.5.4. Safety Moni toring ................................................................................................ 40
10.5.5. Com plaint Handling ............................................................................................. 40
10.6. Appropriateness and Consistency of Measurements ...................................................... 40
10.7. Com pliance .................................................................................................................. 40
11. Sample Si ze and Data Analyses ........................................................................................ 42
11.1. Determinat ion of Sample Size ...................................................................................... 42
11.2. Data Analysis Plans ...................................................................................................... 42
11.2.1. General Considerations ........................................................................................ 42
11.2.2. Study  Parti cipant Disposit ion............................................................................... 42
11.2.3. Study  Parti cipant Characterist ics.......................................................................... 42
11.2.4. Pharmacokinet ic Analyses .................................................................................... 43
I6T-JE-AMAD (a)Protoco l Page 6
LY307482811.2.4.1. Pharmacokinet ic Parameter Estimat ion........................................................... 43
11.2.4.2. Pharmacokinet ic Statistical Inference ............................................................. 43
11.2.5. Pharmacodynamic Analyses ................................................................................. 43
11.2.6. Pharmacokinet ic/Pharmacodynamic Analyses ...................................................... 43
11.2.7. Safety Analyses .................................................................................................... 43
11.2.7.1. Clinical Evaluation of Safet y.......................................................................... 43
11.2.7.2. Statistical Evaluat ion of Safet y....................................................................... 43
11.2.7.3. Evaluat ion of Immunogenicit y........................................................................ 44
11.3. Interim Analyses .......................................................................................................... 44
12. Data Management Methods ............................................................................................... 45
12.1. Data Qualit y Assurance ................................................................................................ 45
12.2. Data Capture Systems .................................................................................................. 45
12.2.1. Source Data and Case Report Form ...................................................................... 45
12.2.2. Ancillary  Data ...................................................................................................... 46
13. Inform ed Consent, Ethi cal Review, and Regulatory  Considerat ions.................................. 47
13.1. Inform ed Consent ......................................................................................................... 47
13.2. Ethical Review ............................................................................................................. 47
13.3. Regulatory  Considerat ions........................................................................................... 47
13.3.1. Invest igator Informat ion....................................................................................... 48
13.3.2. Protocol  Signatures .............................................................................................. 48
13.3.3. Final Report Signature ......................................................................................... 48
14. References ........................................................................................................................ 49
I6T-JE-AMAD (a)Protoco l Page 7
LY3074828List of Tables
Table Page
Table AMAD.1. Invest igational Product Regimens ........................................................... 28
Table AMAD.2. Margin of Safet y for Intravenous Administration of 2400 mg 
LY3074828 Based on Administered Dose and Predicted Exposure ......... 30
I6T-JE-AMAD (a)Protoco l Page 8
LY3074828List of Figures
Figure Page
Figure AMAD.1. Mean percentage change fro m baseline in the Psoriasis Area and 
Severit y Index score by  dose group. ........................................................ 15
Figure AMAD.2. Study  design for Protocol I6T -JE-AMAD. .............................................. 19
I6T-JE-AMAD (a)Protoco l Page 9
LY3074828List of Attachments
Attachment Page
Attachm ent 1. Protocol  AMAD Study  Schedule ............................................................ 51
Attachm ent 2. Protocol  AMAD Clinical Laboratory  Tests ............................................. 54
Attachm ent 3. Protocol  AMAD Bl ood Sam pling Summary ........................................... 55
Attachm ent 4. Protocol  AMAD Blinding/Unblinding Plan ............................................ 56
Attachm ent 5. Protocol  Amendment I6T -JE-AMAD(a) Summary: A Single -Dose 
Study  to Assess t he Safety, Tolerabilit y, and Pharmacokinet ics of 
LY3074828 in Japanese and Caucasian Healt hy Subjects ....................... 58
I6T-JE-AMAD (a)Protoco l Page 10
LY30748284.Abbreviations and Definitions
Term Definition
ADA antidrug antibod y
AE adverse event:  any untoward medical occurrence in a patient or clinical investigation 
subject administered a pharmaceutical product thatdoes not necessarily have a causal 
relatio nship with this treatment.  An AE can therefore be any unfavorable and unintended 
sign (including an abnormal laboratory finding), symptom, or disease temporally associated 
with the use of a medicinal (investigati onal) product, whether or not related to the medicinal 
(investigational) product.
AUC area under the concentration versus time curve
audit A systematic and independent examination of the trial -related activities and documents to 
determine whether the evaluated trial -related activities were conducted, and the data were 
recorded, analyzed, and accurately reported according to the protocol, sponsor’s standard 
operating procedures (SOPs), good clinical practice (GCP), and the applicable regulatory 
requirem ent(s).
blinding aprocedure in which one or more parties to the trial are kept unaware of the treatment 
assignment(s).  Unless otherwise specified, blinding will remain in effect until final 
database lock.
A single -blind study is one in which the investi gator and/o r his staff are aware of the 
treatment but the subject is not, or vice versa, or when the sponsor is aware of the treatment 
but the investigator and his staff and the subject are not. A double -blind study  is one in 
which neither the subject nor any of the investigator or sponsor staff who are involved in 
the treatment or clinical evaluation of the subjects are aware of the treatment received .
CD Crohn’s disease
CI confidence interval
CIOMS Council forInternational Organizations ofMedical Sciences
Cmax maximum drug concentration
complaint acomplaint is any written, electronic, or oral communication that alleges deficiencies 
related to the identity, quality, purity, durability, reliability, safety or effectiveness, or 
performance of a drug or drug delivery system.
compliance adherence to al l the trial -related requirements, good clinical practice (GCP) requirements, 
and the applicable regulatory requirements.
confirmation aprocess used to confirm that laboratory test results meet the quality requirements defined 
by the laboratory generating the data and that Lilly is confident that results are accurate.  
Confirmation will either occur immediately after initial testing or will require that samples 
be held to be retested at some defined time point, depending on the steps required to obtain 
confirmed results.
CRF case report form/electronic case report form:  sometimes referred to as clinical report form ; 
aprinted or electronic form for recording study participants’ data during a clinical study, as 
required by the protocol.
I6T-JE-AMAD (a)Protoco l Page 11
LY3074828CRU clinical research unit
CSE clinically significant event:  amoderate to severe adverse event (AE), abnormal clinical 
sign, or clinical laboratory finding that may pose a risk to the well -being of the subject
CTCAE Common Terminology Criteria for Adverse Events
end of study End of study is the date of the last visit or last scheduled procedure shown in the Study 
Schedule for the last patient /subject .
enroll the act of assigning a subject to a treatment.  Subjects who are enrolled in the trial are those 
who have been assigned to a treatment.
enter Subjects entered into a trial are those who sign the informed consent formdirectly or 
through their legally acceptable representatives.
ERB ethical review board /instit utional review board:  aboard or committee (institutional, 
regio nal, or national) composed of medical professionals and nonmedical members whose 
responsibility is to verify that the safety, welfare, and human rights of the subjects
participating in a clinical trial are protected
GCP good clinical practice:  astandard for the design, conduct, performance, monitoring, 
auditing, recording, analyses, and reporting of clinical trials that provides assurance that the 
data and reported results are credible and accurate and that the rights, integrity, and 
confidentia lity of trial subjects are protected
IB Investigator’s Brochure:  acompilation of the clinical and nonclinical data on the 
investigational product(s) which is relevant to the study of the investigational product(s) in 
human subjects
IBD inflammatory bow el disease
ICF informed consent form
ICH International Conference on Harmonisation of Technical Requirements for Registration of 
Pharmaceuticals for Human Use
IL-12 interleukin -12
IL-23 interleukin -23
informed consent aprocess by which a subject voluntarily confirms his or her willingness to participate in a 
particular trial, after having been informed of all aspects of the trial that are relevant to the 
subject's decision to participate. Informed consent is documented by means of a written, 
signed, and dated informed consent form .  
interim analysis An interim analysis is an analysis of clinical trial data, separated into treatment groups, that 
is conducted before the final reporting database is created/locked.
investigational 
product (IP)A pharmaceutical form of an active ingredient or placebo being tested or used as a reference 
in a clinical trial , including products already on the market when used or assembled 
(formulated or packaged) in a way different from the authorized form, or marketed products 
used for an unauthorized indication, or marketed products used to gain further information 
about the authorized form.
I6T-JE-AMAD (a)Protoco l Page 12
LY3074828investigator A person responsible for the conduct of the clinical trial at a trial site.  If a trial is conducted 
by a team of individuals at a trial site, the investigator is the responsible leader of the team 
and may be called the principal investigator.
IV intravenous
NOAEL no-observed -adverse -effect level
PASI Psoriasis Area and Severity Index
PK pharmacokinetic
randomiz e the process of assigning subjects to an experimental group according to the randomization 
schedule for the trial
rescreen to screen a subject who was previously declared a screen failure for the same study
SAE serious adverse event:  any untoward medical occurrence that at any dose results in death, is 
life threatening, requires inpatient hospitalization or prolongation of existing 
hospitalization, results in persistent or significant disability/incapacity, or is a congenital 
anomaly /birth defect
screen the act of determining if an individual meets minimum requirements to become part of a 
pool of potential candidates for participation in a clinical trial.  In this study, screening 
involves invasive procedures and/or tests (for example, x -rays andblood draws).  For this 
type of screening, informed consent for these screening procedures and/or tests shall be 
obtained; this consent may be separate from obtaining consent for the study.
SC subcutaneous
subject anindividual who is or becomes a participant in clinical research, either as a recipient of the 
investigational product(s) or as a control.  A subject may be either a healthy human or a 
patient.
SUSARs suspected unexpected serious adverse reactions
TB tuberculosis
Th17 T helper 17
TST tuberculin skin test
TEAE treatment -emergent adverse event :  any untoward medical occurrence that either occurs or 
worsens at any time after treatment baseline and which does not necessarily have to have a 
causal relationship with this treatment
TPO third -party organization
I6T-JE-AMAD (a)Protoco l Page 13
LY3074828A Single -Dose Study  to Assess the Safety , Tolerability , and 
Pharmacokinetics of LY3074828 in Japanese and Caucasian 
Healthy  Subjects
5.Introduction
5.1. General Introduction
Interl eukin-23 (IL-23), a member of the interleukin -12 (IL-12) family of cytokines, is a 
heterodimeric protein composed of 2 subunit s:  the p40 subunit, which IL-
23shares wit h IL-12, 
and the p19 subunit, which is believed to be specific to IL -23.  IL -23 is produced by  antigen-
present ing cells, such as dendrit ic cells and macrophages ( Oppm ann et al . 2000 ; Andersson et al. 
2004).  IL -23 is crit ically involved in the maintenance and amplificat ion of T helper 17 (Th17) 
cells.  In addit ion to Th17 cells, many  innate immune cells res pond to IL -23 and are important 
both in resistance to infection and in mediat ing patho logy in many autoimmune or inflammatory  
diseases including ulcerat ive colit is and Crohn’s disease (CD) (Croxford et al. 2014 ).  
Treatment of autoimmune or inflammatory  diseases wi th IL-
23–targeted therapy  is being 
pursued by  many com panies.  The first such bio logic to dem onstrate clinical benefit in 
autoimmune disease was ustekinumab, which is now a napproved m edicine for the treatment of 
patients wi th psoriasis and psor iatic arthrit is (Stelara package insert ,2013) and CD (Toussirot et 
al. 2013).   Ustekinumab is a monoclonal antibody that recognizes the commo n p40 subunit of 
IL-12 and IL -23; therefore, it does not target IL -23 specifically .  
Blockade of the IL -12 pathway
may prevent Th1 cell–induced interferon blo ckade of Th17 cell devel opment, thus potenti ally 
limit ing the clinical act ivity of p40 targeting ant ibodies.  Experimental studies suggest that 
blocking the IL -23/Th17/ interleukin -17 immune axis (and not IL -12) is sufficient to treat 
autoimmune inflammat ion (Monteleone et al. 2009 ).  IL -23–specific medicines targeted to the 
IL-23 p19 subunit have demonstrated clinical act ivity in psori asis and CD (Kopp et al. 2015
; 
Sofen et al . 2014 ; Krueger et al. 2015; Sands et al. 2015 ).  Al though clinical evaluation of an 
IL-
23–targeted therapy  in ulcerat ive co litis has yet to occur, the IL -23/Th17 pathway  is 
suggested to have a significant role in pat ients with ulcerative colit is (Ghei ta et al . 2014 ; Globig 
et al. 2014 ; El-Bassat et al . 2014 ); therefore, evaluation of an IL -23 ant ibody  in this disease 
woul d be the next l ogical step. Therefore, the planned Phase 2 study , I6T -MC-AMAC (AMAC), 
will evaluate the hypothesis that LY3074828 can induce significant ly higher rates of clinical 
remission co mpared to placebo in subjects with moderate to severe ulcerat ive co litis.
LY3074828 is a humanized immunoglobulin G4 –variant m onocl onal ant ibody  that i s directed 
against the p19 subunit of IL -23 and does not bind IL-
12.  LY3074828 is b eing devel oped f or the 
treatm ent of autoimmune diseases in which the IL-23 pathway  is thought to have a significant 
pathogenic role.  LY3074828 does not bind rodent IL
-23, so a surrogate mo lecule was developed 
to neutralize mouse IL -23 for use in preclinic al studi es.  Neutralizat ion of IL -23 wi th this 
surrogate antibody  significant ly reduced the development of arthrit is and inhibited ileal 
inflammat ion in a mouse model o f spondyloarthropathy  with bowel  inflammat ion
(Ruutu et al. 
2012).  In addit ion, neutral ization of IL -23 si gnificant ly reduced the disease score in the 
I6T-JE-AMAD (a)Protoco l Page 14
LY3074828relapsing -remitting experimental autoimmune encephalo myelit is (m ultiple sclerosis –like) m odel 
in mice.  Ant i–IL-23 ant ibody  also dem onstrated som e efficacy  in preclinical arthrit is models, 
depending on the timing of intervent ion (Cornelissen et al. 2013 ).  
One study ,Study  I6T-MC-AMAA (AMAA ): A Phase 1, Randomized, Placebo- Controlled Study  
of LY3074828, an Anti -IL-23 Hum anized Ant ibody in Subjects Wit h and Wit hout Psoriasis ,has 
been completed.  This study evaluated LY3074828 in healt hy volunteers and in subjects with 
plaque psori asis.  Seven cohorts of subjects with active psoriasis received single dose sof
intravenous (IV) LY3074828 (up to 600 mg) or placebo.  A single cohort of 5 he althy subjects 
received single subcutaneous (SC) dosesof LY3074828 (120 mg).  A total of 33 subjects wi th 
psori asis and 5 healt hy subjects were administered LY3074828.   Seven subjects with psoriasis 
received placebo.
No deaths, serious adverse events (SAE s), or di scont inuat ions due to an adverse event 
(AE) were reported.  Treatment -emergent adverse events (TEAEs) reported as related 
to invest igational product (IP)included one Grade 1 event of headache experienced 
by a single subject in the 200 -mg IV cohor t and five Grade 1 events of inject ion site 
pain experienced by  3subjects in the 120- mg SC cohort.  No LY3074828 TEAEs of 
Grade 2 or higher were reported.  No dose -dependent trends in adverse events (AEs) 
were seen.  No clinically  important changes in vit al signs, el ectrocardi ogram s 
(ECGs), or clinical laboratory  resul ts were observed.
Following single IV doses of LY3074828 in Study AMAA, the area under the curve 
(AUC) and maximum drug concentration ( Cmax)increased in approximately a dose-
proporti onal manner.  The mean terminal phase half -life across all IV doses was 10.5 
days and did not appear to be dependent on dose, and the mean clearance is wit hin the 
range expected for human mo noclonal antibodies.  The overall mean clearance across 
all doses f ollowing IV administration was approximately 0.526 L/day  and is wi thin 
the range expected for human monoclo nal ant ibodies.  Maximum concentrations were 
observed 3 days postdose fo llowing SC administration.  Based on the AUC, the SC 
bioavailabilit ywas 40% relative to IV administration. 
Immunogenicit y evaluat ions were performed in Study  AMAA.  Bl ood sam ples to 
evaluate anti-drug ant ibodies ( ADA )were collected at baseline and approximately 22, 
43, and 85 days postdose.  ADA data were available for 45 subjects, 38 who received 
LY3074828 and 7 who received placebo.  All subjects who received placebo were 
ADA negat ive at baseline and postbaseline.  Only one subject who received 
LY3074828 was positive at baseline.  Thirt y-one subjects who received LY30 74828 
(81.6%) were negative at all postbaseline t ime points evaluated.  Seven subjects who 
received LY3074828 had a postbaseline posit ive titer; however, only 3 of those 
subjects (7.9% of LY3074828 -treated individuals) developed treatment -emergent 
ADA, def ined as a 4-fold or greater change in t iter fro m baseline.  None of these 
cases o f treatm ent-emergent anti -drug ant ibodies (TE -ADA) were associated with 
treatm ent-
emergent adverse events (TEAEs). 
I6T-JE-AMAD (a)Protoco l Page 15
LY3074828In Study  AMAA, clinical act ivity was expl ored in subjects w ith psoriasis, with a 
follow-up period of approximately  12weeks.  Figure AMAD. 1presents mean data by  
cohort for the percentage change in the Psorias is Area and Severit y Index (PASI) 
score.  The PASI measures the severit y of disease on a scal e from 0 to 72 (in which a 
score of 72 indicates extreme disease severit y) by combining assessments of the 
extent of body  surface invo lvement in the head, trunk, a rms, and legs wit h the 
severit ies of desquamat ion, ery thema, and plaque indurat ion.  Preliminary PASI data 
show improvement of psoriasis after a single dose of LY3074828 in the higher -dose 
cohorts.
Figure AMAD. 1. Mean percentage change from baseline in the Psoriasis A rea and 
Severity Index score by dose group .
Phase 2 studies investigat ing the efficacy of LY3074828 as a potential treatment for psoriasis 
(AMAF), ul cerat ive colit is (AMAC), and Crohn’s disease (AMAG) are currently ongo ing.   
Phase 1 Study I6T-JE-AMAD (AMAD ) will provide safet y, tolerabili ty, and pharmacokinet ic 
(PK)data after IV and SC administration of LY3074828 in Japanese and Caucasian healt hy 
subjects.
More informat ion about the known and expected benefits, risks,and reasonably anticipated AEs
may be found in the Investigator’s Brochure (IB).  Inform ation on AEs expected to be related to 
the IPmay befound in Section 6 (Development Core S afety Informat ion)of the IB .  Change in PASI (%)
    -110    -100     -90     -80     -70     -60     -50     -40     -30     -20     -10       0      10      20
Planned Study DayBaseline 15 29 43 57 71 85Placebo
5 mg
20 mg
60 mg
120 mg
200 mg
350 mg
600 mg
I6T-JE-AMAD (a)Protoco l Page 16
LY30748285.2. Rationale and Justification for the Study
This study  intends to characteri ze the safet y,tolerabili ty, and PKof LY3074828 after single- dose 
administration in healt hy Japanese and Caucasian subjects .  Characterizat ion of safet y and PK in 
Japanese subjects isessent ial for further cl inical  devel opment in Japan .
I6T-JE-AMAD (a)Protoco l Page 17
LY30748286.Objectives
6.1. Primary  Objective
The primary  object ive is to expl ore the safet y and tolerabili ty of LY3074828 in healt hy Japanese 
and Caucasian subjects to define an appropriate dose for further clinical research in Japan .
6.2. Secondary Objective s
The secondary  objective sof this study  are
to estimate the PK parameters of LY307482 8following IV and SC administration in healt hy 
Japanese and Caucasian subjects
t
o explore the safet y, tolerabilit y, and PK of LY3074828 inJapanese subjects in relat ion to
Caucasian subjects
I6T-JE-AMAD (a)Protoco l Page 18
LY30748287.Investigational Plan
7.1. Summary of Study Design
This is asingle- site,subject -and invest igator -blind, randomized, placebo -controlled, single -dose 
study  to assess the safet y, tolerabilit y, and PKof LY3074828 in Japanese and Caucasian healt hy 
subjects. Subjects will be rando mized to LY3074828 or placebo within1 of 6cohorts , as shown 
in Figure AMAD. 2.  Co hort 1will consist of 10 subjects (6 Japanese and 4 Caucasian) who will 
be randomized so that 5 Japanese subje cts and 3 Caucasian subjects will receive LY3074828 
while 1 Japanese subject and 1 Caucasian subject will receive placebo .  
Cohorts 2 through 6 will 
consist of 8 subjects (4 Japanese and 4 Caucasian) who are randomized in a 3:1 ratio of 
LY3074828 to placebo.  For each cohort, 3 Japanese subjects and 3 Caucasian subjects will 
receive LY3074828 while 1 Japanese subject and 1 Caucasian subject will receive placebo.  
Single doses up to 600 mg IV have been studied and shown to be well tolerated, therefore all 
cohorts, with the exception o f Cohort 5 and Cohort 6 , may be dosed in parallel if the site is able 
to accommodate more than 1 cohort at a time.   Cohort 5 will be dosed after confirming the safet y 
and PK data from Cohort 1. Cohort 6 will be dosed last after confirming the safet y and PK data 
from Cohort 5. Two addit ional Japanese subjects will be included in Cohort 1 to ensure that a 
sufficient number of Japanese subjects will have received LY3074828 at the time of the interim 
analysis .  An interim analysis is planned based on Cohort 1data through Day 15(see Section 
11.3)to support Japanese pat ients being included in the planned g lobal Phase 2 study , Study  I6T-
MC-AMAC (AMAC) .
I6T-JE-AMAD (a)Protoco l Page 19
LY3074828Abbreviations:  FU=follow up; IV=intravenous; SC =subcutaneous.
Figure AMAD. 2. Study design for Protocol I6T-JE-AMAD .
Treatment :  
Four IV dose levels and 1 SC dose level of LY3074828 will be assessed in Cohorts 1through 6.  
The fo llowing treatm ents are planned :
Cohort 1: asingle dose of LY3074828 600 mgor placebo IV
Cohort 2: asingle dose of LY3074828 200 mgor placebo IV
Cohort 3: asingle dose of LY3074828 200mgor placebo SC
Cohort 4: a single dose of LY3074828 6
0mg or placebo IV
Cohort 5: asingle dose of LY3074828 1200mgor placebo IV
Cohort 6: a single dose of LY3074828 2400 mgor placebo IV
Study Procedures:   
Each subject will have a screening visit within28days pri or to dosing , as show nin the Study 
Schedule (Attachment 1 ).  AEs, including inject ion-site reacti ons, will be assessed on all clinical  
research unit ( CRU )visit days and when spontaneously reported. Physical examinat ion,vital 

I6T-JE-AMAD (a)Protoco l Page 20
LY3074828signs, ECG s, laboratory  tests , PK and other sample collect ionswill be perform ed at times 
specified in the Study Schedule (Attachment 1 ).  
Subjects will report to the CRU on Day  –2and remain at the CRU unt il after the scheduled 
procedures have been co mpleted on Day 2(Attachment 1 ).  
After randomization, study  drug will 
be administered by eitherIV or SCinject ionin the morning of Day 1 afteran overnight fast.
Extensio n of admissio n to the CRU and addit ional outpati ent visi ts may  be requi red for saf ety 
reasons at the discret ion of the invest igator.  If any safet y findings warrant follow -up and/or 
precl ude discharge fro m the study , further visits may  be arranged a s appropri ate.
Sequent ial PK sampling and safet y monitoring will  occur through the end of study .  There will 
be outpati ent vi sits over approximately 12weeks after study  drug administrati on, including an 
End of Study  visit(Day 85)thatwill occur approximately 12weeks after the dose.
7.2. Discussion of Design and Control
This is a single -site, subject -and invest igator -blind, randomized, placebo -controlled, single -
dose 
study  in healthy Japanese and Caucasian subjects.   Healthy Caucasian subjects are i ncluded in 
this study  to enable compar ison between healt hy Japanese and Caucasian subjects , as most of the 
subjects in Study  AMAA were Caucasian pat ients with psoriasis .  The number of subjects in 
Study AMAD is not sufficient for any  formal ethnic comparison ,but the safet y, tolerabili ty, and 
PK data will be assessed in both Japanese andCaucasian subjects and will be used to support the 
inclusio n of Japanese subjects in future studies involving LY3074828.   The study  will be 
subject -and invest igato r-blind, with the subjects , investigators ,andsite staff (except for site 
pharmacy staff) unaware of actual treatment (LY3074828 or placebo), but aware of dose l evel 
assigned to the cohort .  This design is being used to minimize bias in safet y and tol erability 
assessments.
Dosing will begin withthe 600 mgIVcohort because the timing of thiscohort will determine the 
timing of the interim analysis and subsequent inclusion of Japanese subjects in the LY3074828 
global studi es.  Single doses up to 600 mghave al ready  been shown to be well tolerated in 
StudyAMAA .  The dose levels included in this single -dose study  are within the range of doses 
studi edprevi ously , with the except ion of the planned 1200 mg and 2400 mgIV dose cohort .  
Preliminary populati on PK analyses of interim data from Study  AMAA indicate that body  
weight has no clinically significant impact on clearance or volume of distribution of LY3074828.  
Therefore ,the AUC and maximum drug concentration (
Cmax) in Japanese subjects who may
have lower body  weight areexpected to be similar to those ofsubjects in Study  AMAA .
The follow-up period will be 12 weeks for allcohorts after dos ing. This durati on will  allow 
ample time for assess ment of the PK of LY3074828 (>5half-lives) and for aninitial assessment 
of ADA s.  
I6T-JE-AMAD (a)Protoco l Page 21
LY30748288.Study  Population
8.1. Criteria for Enrollment
Eligibilit y of subjects for study enrollment will be based on the results of a screening medical 
history , physical  examinat ion, vital signs, electrocardi ogram  (ECG) , and clinical labor atory  tests
(Attachm ent 1 ).  
A chest x-raywill be com pleted at screening unless one has been obtained within the past 
12months,and the x -ray and/or report are available for the investigator’s review.
The nature of any condit ions present at the time of the physical examinat ion and any preexist ing 
condi tions will  be docum ented.
Screening may occur up to 28 days prior to dosing .  Subje cts who are not enrolled within 28days
of screening m ay be subjected to an addit ional medi cal assessment and/or clinical measurements 
to confirm their eligibilit y.
Individuals who do not meet the criteria for participation in this study  (screen failure) maynotbe 
rescreened .  Ho wever ,if individuals have met the criteria for participation in this study but their 
screening assessments were collected outside of the 28 -dayscreening window, those assessments 
may be repeated.
Prospective approval o f protocol  deviati ons to recrui tment and enro llment criteria , also known as 
protocol  waivers or exempt ions,are not permitted.
8.1.1. Inclusion Criteria
Subjects are eligible for enrollment in the study only if they meet all o f the following cri teria:
[1] are overtly healt hy males or females, as determined by  medical history  and 
physical examinat ion
[1a] male subjects :
will be sterile (including vasectomy) or agree to use a reliable method of 
birth control and will not donate sperm during the study andfor 3months 
following administrati on of  the study  drug
[1b] female subjects :
are wom en of childbearing potential who test negative for pregnancy before 
receiving study  treatm ent based on serum pregnancy  test and agree to use a reliable 
method of birth control (for example:  barrier m ethods such as condom, sponge, or 
diaphragm  combined wi th spermicide in foam, gel, or cream; hormonal 
contraception [oral, intramuscular, implant, or transdermal], which includes 
Depo -Provera, Evra, and NuvaRing; intrauterine device; or complete abstinence
from sexual  intercourse with men ) during the study  and for 3months fo llowing
administration of the study  drug
or
I6T-JE-AMAD (a)Protoco l Page 22
LY3074828are women not of childbearing potenti al due to surgi cal sterilizat ion (at least 
6weeks afterbilateral oophorectomy and/or hysterec tomy or at least 6 weeks after
tubal  ligation) confirmed by medical history , or postmenopaus al, defined as eit her:
1) spon taneous am enorrhea for at l east 12 months, not induced by a medical 
condi tion ormedicat ions
or
2) spontaneous amenorrhea for 6to 12monthswitha follic le-stimulating hormone 
level greater than 40 mIU/mL at screening
[2] are first-generat ion Japanese or are Caucasian .   
 
[3] are 20years to 64 years, inclusive, at the time of initial screening
[4] have a body  mass index (BMI) of 18.0 kg/m 2to32.0kg/m 2,inclusive , at 
screening
[5] have a body  weight of  40.0kg or higher for Cohort s
1to4and 48.0 kgor 
higher for Cohort5and Cohort 6
[6] have clinical laboratory  test resul ts wi thin norm al reference range for the 
popul ation or invest igator site, or results with acceptable deviat ions th at are 
judged to be not clinically significant by  the investigator
[7] have venous access sufficient to allow for blood sampling and administration 
of IPas per the protocol
[8] a
re reliable and willing to make themselves available for the duration of the 
study  and are willing to follow study  procedures
[9] have given wri tten informed consent approved by  Lilly and the ethical review 
board ( ERB )governing the site
8.1.2. Exclusion Criteria
Subjects will be excluded fro m study enrollment if they meet any o f the following criteria:
[10] are invest igator site personnel directly affiliated with this study and their 
immediate families.  Immediate family is defined as a spouse, parent, child, or 
sibling, whether bio logical or legally adopted.
[11] are Lilly  empl oyees or em ployees of the third-party  organizati o ns(TPO s )
involved with the study
[12] are currently enrolled in a clinical  trial involving an IPor off -label use of a 
drug or device or are concurrent ly enro lled in any other type of medical 
research judged not to be scient ifically or m edically  com patible with this 
study
CCI
I6T-JE-AMAD (a)Protoco l Page 23
LY3074828[13] have participated, within the last 30days,in a clinical  trial invo lving an IP. If 
the previous IPhas a long half-life, 3months or 5 half-lives (whichever is 
longer) should have passed .
[14] are persons who have previously completed or withdrawn fro m this study  or 
any other study  invest igating LY3074828 or any  other anti-IL-23 ant ibody
and have previously  received the IP
[15] have known allergies to LY3074828 , related compounds including humanized 
monoclonal antibodies ,or any  com ponents of the formulation or history  of 
significant atopy
[16] have clinically  significant m ultiple or severe drug allergies, intolerance to 
topical corti costeroi ds, or severe posttreatment hypersensit ivity react ions 
(including but not limited to ery thema mul tiforme major, linear 
immunogl obulin A (IgA) dermatosis, toxic epidermal necrolysis, or 
exfoliative dermat itis)
[17] have an abnorm ality in the 12 -lead ECG that, in the opinion o f the 
investigator, increases the risks associated with parti cipat ing in the study
[18] have an abnormal blood pressure as determined by the investigator
[19] have a significant history  of or current cardiovascular, respiratory, hepatic, 
renal, gastrointestinal, endocrine, hematological , or neurol ogical disorders 
capable of significant ly altering the absorption, metabolism, or eliminat ion of 
drugs; of const ituting a risk when taking the study  medicat ion; or of 
interfering wi th the interpretati on of  data
[20] have known or ongoing psychiatric disorders
[21] regularly use known drugs of abuse and/or show posit ive findings on urinary 
drug screening
[22] show evidence of human immunodeficiency  virus (HIV) infection and/or 
positive human HIV ant ibodies at screening
[23] show evidence of hepatit is C and/or positive hepat itis C ant ibody at scre ening
[24] show evidence of hepatit is B and/or positive hepat itis B surface antigen or
positive hepat itis B core antibody (HBcAb+) at screening
[25] are wom en who are lactating
[26] have used or intend to use over -the-counter or prescript ion medication,
including herbal medicat ions,within 14days prior to dosing (stabl e doses of 
oral contraceptive, hormone replacement therapy ,or vitamins at usual  doses 
may be allowed as per judgment of the invest igator)
[27] have donated blood of more than 500mLwithin the l ast m onth
I6T-JE-AMAD (a)Protoco l Page 24
LY3074828[28] are subjects who have an average weekly alcoho l intake that exceeds 21units 
per week for malesand 14 units per week for females or who are unwilling to 
abide by  the alcoho l restri ctions described in Section 9.5
[29] are subjects whose t obacco consumpt ion is mo re than 10 cigarettes per day  or 
the equivalent or subjects who are not willing to refrain fro m smoking f or 
approximately 2hours prior to each ECG and vital-sign measurement during 
the study or who are unwilling to abide by  the CRU sm oking gui delines 
(Secti on 9.5)
[30] have had symptom atic herpes zoster wi thin 3 months of screening
[31] show evidence of active or latent tuberculosis (TB) , as documented by 
medical history  and examinat ion, chest x -rays (posteri or anteri or and l ateral ), 
and TB testing:  to qualify for the study , subject must have either a negat ive 
tuberculin skin test (TST; defined as a skin induratio n <5 mm at 48 hours to 
72hours, regardless of BCG [Bacillus Calmette -Guerin ] or other vaccinat ion 
history ),or a negative (not indeterminate) QuantiFERON ®-TB Gold test.  The 
choice to perform a TST or a QuantiFERON -TB Gol d test will be made by 
the invest igator according to local licensing and standard of care.
[32] have received live vaccine(s) within 1 month of screening or intend to during 
the study
[33] are immunocompro mised
[34] have received treatment wi th biologic agents (such as m onocl onal antibodies , 
including marketed drugs ) within 3 months or 5 half-lives (whichever is 
longer) prior to dosing
[35] have had lympho ma, leukemia, or any  malignancy  within the past 5 years 
except for basal cell or squamous epithelial carcinom as of  the skin that have 
been resected with no evidence of metastatic disease for 3 years
[36] have had breast ca ncer within the past 10 years
[37] in the opinio n of the invest igator or sponsor are unsuitable for inclusio n in the 
study for any  reason
8.1.3. Rationale for Exclusion of Certain Study Candidates
Criteria [ 10] and [ 11] prevent conflict of interest in study  parti cipants.  Cri teria [12] through [ 37] 
exclude medical condit ions, m edicat ion intolerance, and concomitant medicat ion use that may 
const itute a risk for the subject and/ormay confound the assessment of study  endpoints.
8.2. Discontinuation
The reason for and date of discont inuat ion will be collected for all subjects .  All randomized
subjects who discontinue afterreceiv ingstudy  drug will have procedures performed as shown in 
the Study  Schedule ( Attachm ent 1 ).
I6T-JE-AMAD (a)Protoco l Page 25
LY30748288.2.1. Discontinuation of Subjects
8.2.1.1. Subjects Inadvertently Enrolled
The cri teria for enrollment m ust be fo llowed explici tly.  If the invest igator site ident ifies a 
subject who did not meet enrollment criteria and who was inadvertently enro lled, the sponsor 
must be notified.  If the sponsor ident ifies a subject who did not meet enro llment criteria and 
who was inadvertent ly enro lled, the invest igator site will be notified.  A discussio n must occur 
between the Lilly  clinical  pharmacol ogist or clinical  research physician and the invest igator to 
determine whether the subject may  cont inue in the study  without IP.  The subject may not 
continue in the study  if the Lilly clinical pharmacologist or clinical research physician does not 
agree wi th the invest igator’s determinat ion it is medi cally appropri ate for the subject to continue.  
The inve stigator must obtain documented approval fro m Lilly clinical pharmacologist or clinical 
research physician to allow the inadvertently enro lled subject to continue in the study.
8.2.1.2. Discontinuations from Investigational Product or from the Study
Subjects will b e discont inued fro m the IPand/or from the study  in the fo llowing ci rcumstances:
enrollment in any other clinical trial involving an IPor enrollment in any other ty pe of 
medical research judged not to be scient ifically or medically co mpat ible with this study
investi gator decisio n
othe invest igator decides that the subject shoul d be discontinued from the study
subject decisio n
othe subject requests to be discontinued from the study
sponsor decisio n
oLilly stops the study  or stops the subject ’s participation in the study  for medical, 
safet y, regul atory , or other reasons consistent with applicable laws, regulat ions, 
and good clinical pract ice (GCP )
adverse event 
oif a clinically  significant event (CSE) occurs during the IV infusio nor SC 
inject ion, the IPis to be discont inued and appropriate measures taken.  Lilly or its 
designee should be alerted immediately.  A CSE will be defined as a moderate to 
severe AE, abnormal clinical sign, or clinical laboratory  finding that may  pose a 
risk to the well-being of the s ubject.  Refer to Safety  Evaluat ions (Secti on
 10.5).
oaclinically significant systemic hypersensit ivity reacti on occurs fo llowing 
administration of the IP(for example, drug -related symptomat ic bronchospasm, 
allergy -related edem a/angi oedema, or hy potensi on) that requi res parenteral  
medicat ion, does not respon d to symptomat ic medication, or results in clinical 
sequelae or an anaphylact ic react ion
I6T-JE-AMAD (a)Protoco l Page 26
LY3074828A dose group may be discontinued from the IPif the fo llowing are m et:
2or more subj ects/cohort develop AEs that are severe, unless there is an obvious 
explanat ion other than IPor study procedures for the event(s)
OR
if greater than 40% of  subjects in a cohort experience moderate treatment -related AEs 
that impair normal act ivities
OR
after the introduction of premedicat ion in accordance with the protocol, 2 or more 
subjects develop (according to Commo n Termino logy Criteria for Adverse Events 
[CTCAE] , versi on4.0) Grade 2 acute AEs related to the infusio n, during or wi thin 
2hours of complet ing the infusio n,that do not resolve with a reduced infusio n rate and/or 
supportive care
Following the invest igator’s determinat ion that CSE criteria have been met and the invest igator’s 
judgment of relatedness to the IPis documented, a decisio n will be made between the 
investigator and Lilly or its designee regarding subject dis continuat ion.
The nature of any condit ions, clinical signs or symptoms, or abnormal laboratory  values present 
at the time of discont inuat ion and any applicable follow -up procedures will be documented.
Refer to the Study  Schedule (Attachm ent 1 )for data collected at the time of discont inuat ion.
8.2.1.3. Subjects Lost to Follow -up
A subject willbe considered lost to follow -up if he or she repeatedly  fails to return for scheduled 
visits and is unable to be con tacted by  the study  site.  Site personnel are expected to make 
diligent attempts to contact subjects who fail to return for a scheduled vis it or were otherwise 
unable to be fo llowed up by  the si te.
8.2.2. Discontinuation of Study Sites
Study  site parti cipat ion may be discont inued if Lilly, t he invest igator, or the ERB of the study  
sitejudges it necessary for any reason consistent wit h applicable la ws, regul ations, and GCP .
8.2.3. Discontinuation of the Study
The study  will be di scontinued if Lilly judges it necessary for medical, safet y, regul atory , or 
other reasons consistent with applicable laws, regulat ions, and GCP.
I6T-JE-AMAD (a)Protoco l Page 27
LY30748289.Treatment
9.1. Treatment Materials and Su pplies
LY3074828 will be supplied to the invest igator by Lilly.  Clinical trial materials are 
manufactured in accordance wit h good m anufacturing practices.  All IPs will be stored, 
inventori ed, reconciled, and destroy ed according to applicable regulat ions.
LY3074828 is supplied for clinical trial use as lyo philized powder in a glass vial and should be 
stored in refrigerated condit ions (2ºC to 8ºC).  The vial is manufactured to deliver 75 mg of 
LY3074828 and will be reconst ituted before administration.  Deta iled instructions for the 
preparati on and handling of LY3074828 will be provided by  the sponsor.
When reconst ituted and in a sy ringe, LY3074828 cannot be distinguished visually  from placebo .  
Subjects and blinded site staff will not be able to see the diff erence because the label on the 
syringe will cover the solut ion.See Table AMAD. 1for addit ionaldetails regarding the IP 
regimens. 
Placebo will  be sterile norm al saline (0.9% sodi um chl oride), which shoul d be supplied by 
investigat ive site(s).
Clinical trial materials w ill be labeled according to the country ’s regul atory  requi rements.
9.2. Treatment Administration
The invest igator or designee is responsible for:
explaining the correct use of the investigational agent(s) to the subject/site personnel , 
verifying that instructi ons are fo llowed properly,
maintaining accurate records of IPdispensing and collect ion,
and returning all unused medicat ion to Lilly or its designee at the end of the study .
Note : In some cases, sites may destroy  the m aterial  if, during the invest igator site sel ection, the 
evaluator has verified and documented that the site has appropriate facilit ies and wri tten 
procedures to dispose ofclinical trial materials .  
Subjects will be instructed to contact the invest igator as soon as possible if he or she has a 
complaint or probl em wi th the IPso that the situation can be assessed.
All clinical trial material provided to the invest igator will be stored in a secure place, and 
allocated and dispensed by appropriately trained persons.  The allocat ion and dispensing of the 
IPs will be fully documented and verified by a second person.  De tailed records of the amounts 
of the IPreceived, dispensed, and remaining at the end of the study  will be m aintained.
The actual  time of all dose administrations will be recorded in the subject’s case report form 
(CRF).
I6T-JE-AMAD (a)Protoco l Page 28
LY3074828The IPwill be administered as a sl ow IV infusio n ofat least 30minutes.  SC administration of 
LY3074828 will be given as 2inject ionsof 1.4mLinto the skinfo ld of the left or right 
abdo minal wall. Sites m ust have resuscitat ion equipment, emergency drugs, and appropriately  
trained staff available for at least 6hours after the start of theinfusio nor postdose for SC 
administration .
Table AMAD. 1. Investigational Pro duct Regime ns
LY3074828 or Placebo
Cohort Cohort 1 Cohort 2 Cohort 3 Cohort 4 Cohort 5 Cohort 6
Regimen 600mg IV 200mg IV 200mgSC 60mgIV 1200 mgIV 2400 mg IV
LY3074828 concentration 25 mg/mL 20 mg/mL 72 mg/mL 6 mg/mL 25 mg/mL 25 mg/mL
Volume per dose
24mL 10mL2.8mL
(1.4 mL ×
2injections)10mL 48 mL 96 mL
Abbreviations:  IV =intravenous; SC =subcutaneous.
9.3. Rationale for Selection of Dose
The 5IV doses for this study  are 60, 200, 600, 1200, and 2400 mg and the SC dose for this study 
is 200 mg.
Thelow dose of 60 mg IV for this study  ischosen as one of the doses that was administered in 
the global single -dose study  (Study AMAA ) andis close to the low dose in the Phase 2 
ulcerat ive co litis study  (Study AMAC ).
The 200-mgIV dose is one of the starting dose sin Study  AMAC and is one of the doses that was 
administered in Study  AMAA .  
A dose of 200 mg SC is being administered in the maintenance
period of  Study  AMAC .
The 600-mg IV dose is the highest dose being tested in Study  AMAC and is the highest dose that 
wasadministered in Study  AMAA .
The ori ginal  highest dose of 1200 mgIV was tested for safet y and tol erabili ty based on the safet y 
resul t
sat each escalat ion cohort of  this study . Findings from these resul ts support edthe highest 
dose of1000 mg IV inthe Phase 2 Crohn’s disease study  (Study AMAG ).
The amended maximum dose of 2400 mg IV isselected to support potential future studi es in 
patients with ulcerat ive colitis and Crohn’s disease, where high IV doses (potentially beyo nd 
1200 mg) during induct ion treatm ent may be requi red to maximize efficacy (Sandborn et al. 
2012; Adedokun et al. 2016; Feagan et al. 2016).
The margin o f safet y at 2400 m g IV is 1.9-fold.  This value is based on the predi cted exposure at
2400 mg compared to the observed exposure at 100 mg/kg IV, administered once weekly, in the 
4-week ,repeat -dose m onkey  study.  In thi s study , 100 m g/kg was the no observed adverse -effect 
level ( NOAEL ) and also the highest dose tested. ( seeTable AMAD. 2).
LY3074828 does not recogni ze rodent IL-23, which precludes its use in preclinical toxicity 
assessment and in efficacy  disease models.  Themonkey is a pharmaco logically  relevant species 
I6T-JE-AMAD (a)Protoco l Page 29
LY3074828for assessing nonclinical toxici ty because LY3074828 binds with similar affini ty to human and 
cyno molgus IL-23 (21pM and 55 pM, respectively).  To assess the toxicity of LY3074828 and 
establish a margin of safety for clinical trials (Table AMAD. 2), 4-week and 6-mont h toxicity 
studi es in norm al cynomolgus monkeys were perform ed with evaluat ion of safety pharmaco logy 
as part of the 4-week study . The weekly  administrati on of LY3074828 tocyno molgus monkeys 
resul ted in no adverse drug-related findings at doses of 0mg/kg (vehicle), 1mg/kg and 
30mg/kg (SC), or 100mg/kg (IV) for 4weeks, with an 8-week recovery  period, or at doses of 
0mg/kg , 10mg/kg , and 100 mg/kg (SC) for 6months.  Therefore , the NOAEL was 
100mg/kg/week for both studies ; this was the highest dose tested. A safet y pharm acology 
assessment performed during the 4- week monkey  study  included evaluat ion of body  temperature, 
cardi ovascular safet y (including quant itative evalu ation of ECG measurements and quali tative 
evaluat ion for abnorm al wavef orm morphol ogy and arrhy thmias ),observat ions for central 
nervous system  signs with neurol ogic examinat ions, and qualitat ive assessments of respiratory 
depth wi th quanti tative est imates of respi ratory  rate.  No drug -related changes occurred i n any of 
these parameters.
Due to a l ack of a preclinical disease model, the anti cipated minimally effect ive dose for 
LY3074828 is unknown.   
The clinical dose range for LY3074828 is not yet known , and the 
maximum planned LY3074828 dose level to be evaluated in Study AMAC is 600mg.  However, 
it is possible that dose levels higher than 600mg could be required in certain pat ients (for 
example, those with more severe disease act ivity) to achieve highe r exposures in pat ients with 
inflammatory  bowel disease ( IBD
),in part due to greater clearance observed in these pat ients 
(Ord ás et al. 2012). Higher drug exposures, particularly during an induct ion dosing period
(Yarur et al. 2014) , may be requi red to s upport the best clinical outcomes in many auto -
inflammatory  disease indications, including IBD.  
Therefore, this study  plannedtoevaluate the safet y, tolerabilit y, and PK of a 1200- mg IV dose of 
LY3074828.  The1200-mg IV dose cohort (Cohort 5) wasdosed after safet y ,tolerabili ty, and 
PK data were confirmed fromthe 600-mg dose cohort (Cohort 1). Other dose l evels weredosed 
concurrent ly in this study because the sedoses have al ready  been shown to be well tolerated in 
Study AMAA .Evaluat ion of 1200-mg IV dose cohort (Cohort 5) provided safet y and PK data to 
support the use of a higher dose level i n Study  AMAC and Study AMAG . 
In addit ion to the above evaluat ion, this study  is amended to add the evaluat ion ofsafet y, 
tolerabilit y, and PK of a 2400
-mg IV dose of LY3074828, since there is a possibilit y to evaluate 
a higher dose level up to 2400 mg IV in later clinical development.  The proposed dose of 
2400- mg IV infusio n has a sufficient margin of safe ty in term s of dose. Moreover , the clinical 
safety profile of LY3074828 available to date support s 2400- mg IV administration in this study.  
Single doses of up to 1200 mg IV were evaluated in healt hysubjects fro m Study  AMAD andno 
dose-related safet y or tol erabilit y issues were observed.  Evaluat ion of the safety  data available 
to date in the ongoing Study  AMAC and Study  AMAG that are evaluating higher and more 
frequent dose regimens o f up to 1000 mg IV Q4W for up to 52 weeks ha s not reveal ed any 
difference sin the safet y profile.  The PK profile of this drug was found to be approximately
linear up to 1200 -mg IV administration. Since the 2400
-mg IV dose is only 2-fold of 1200 mg, it 
I6T-JE-AMAD (a)Protoco l Page 30
LY3074828is unlikely  that an unexpected PK profile will be observed after administration of a 2400- mg IV 
dose.Therefore, evaluation o f this addi tional higher dose cohort (2400 m g)will provide safet y 
and PK data to support the use of a higher dose level beyo nd 1200 m gduring the clinical 
development of this compound.
Table AMAD. 2
. Margin of Safety for Intravenous Administration of 2400mg 
LY3074828 Based on A dministered Dose and Predicted Exposure
Dose (mg/kg) Dose Multiple aAUC 0-672h,ss
(gh/mL)Margin of Safety b
Human highest 
dose (2400 mg) c36.9 (IV) 110000
Monkey NOAEL d
6-month study100 (SC) 2.7 85800 e 0.78
Monkey NOAEL f
4-week study100 (IV) 2.7 204200 g 1.9
Abbreviations:  AUC =area under the concentration vs time curve; AUC 0-672h,ss =AUC over 672 hours at steady 
state; AUC 0-168h= AUC over 168 hours; AUC 0-∞  = AUC from time zero to infinity; Cmax= maximum drug 
concentration; I V =intravenous; NOAEL =no observed -adverse -effect level; SC =subcutaneous.
aDose multiple is the dose in animals divided by dose in humans.
bMargin of safety is the calculated mean AUC in animals divided by predicted mean AUC in humans after 
adjusting for differences in dosing frequency.
cHighest proposed dose in this study; a body weight of 65 kg is assumed.  Human AUC 0-672h,ss isequivalent to 
the expected AUC 0-∞following a single dose.  Human AUC 0-672h,ss at 2400 mgIV is predicted on the basis of 
the average IV clearance (
0.526 L/day )from Study I6T-MC-AMAA .  AUC and C maxwere observed to increase 
in proportion to dose in Study I6T-MC -AMAA .
dNOAEL was determined in a 6- month repeat dose toxicity study (Study 20043324).
eMonkey AUC value was based on average of male and female Day 176 means of AUC 0-168hand has been 
multiplied by 4 to align with the 4 -week AUC interval projected for humans and planned for Phase 2 
StudyI6T-MC -AMAC .
fNOAEL was determined in a 1-month repeat -dose toxicity study ( Study  20029153) .  
gMonkey  AUC value was based on average of male and female Day 29means of AUC 0-168hand has been 
multiplied by 4 to align with t he 4-week AUC interval projected for humans and planned for Phase 2 
Study I6T-MC -AMAC .
9.4. Dose Escalation
All doses in this study , with the except ion of the 1200 -mg and 2400- mg dose s, have been
previously tested and shown to be well tolerated in Study AMAA.  The only dose escalat ion 
decisio n
sin this study  will be made to proceed from the 600-mg cohort (Cohort 1) to the 1200 -
mg cohort (Cohort 5) and the 1200- mg cohort (Cohort 5) to the 2400- mg dose cohort (Coho rt6).
Safety and PK data reviewed at the time of the first interim analysis will be used for the 
escalat iondecisio n to the 1200- mg dose.  Safet y and PK data up to the 1200 -mg dose cohort will 
be reviewed before dose escalat ion to 2400 mg.   
Thedose escalat ion can notoccur without prior 
discussio n and agreement between the invest igator and the Lilly clinical pharmaco logist.  
I6T-JE-AMAD (a)Protoco l Page 31
LY30748289.4.1. Dose Escalation Method
Safety data, in particular AEs, SAEs ,and adverse laboratory  abnorm alities, will be 
independent ly assessed by the invest igator, and will be considered related to the IPunless there 
is clear evidence that the event is not related.  The assessment of AE relatedness is detailed in 
Secti on10.5.1 .  PK data included in the interim analysis will also be assessed .  
After review of the data, an agreement on the appropriate dose escalation wil l be made by  the 
investigator and sponsor for Cohort 6. None of the following scenarios occur red at 1200 -mg 
LY3074828:
2or more subjects develop AEs that are severe, unless there is an obvious explanation 
other than IPor study  procedures for the event(s )
OR
if greater than 40% of  subjects experience moderate treatment -related AEs that impair 
norm al activities
OR
after the introduction of premedicat ion in accordance with the protocol, 2 or more 
subjects develop (according to Commo n Termino logy Criteria for Adverse Events 
[CTCAE]) Grade 2 acute AEs related to the infusion, during or within 2 hours of 
completing the infusio n, that do not resolve with a reduced infusio n rate and/or 
supportive care .
9.5. Specifi c Restrictions/Requirements
Prior to beginning the study , the subjects will complete informed consent. Throughout the study , 
subjects may  undergo medical  assessments and review of compliance wit h restrict ionsbefore 
continuing in the study .
Meals/Diet —Sub jects shoul d fast overnight for at least 8 hours before dosing (water permitted)
and before each labo ratory  test.
Caffeine —Subjects shoul dnot be allowed caffeine consumpt ion for 12hours prior to CRU 
admissio n
sand when in the CRU. At other times during the outpati ent peri od,subjects will be 
allowed to maintain their regular caffeine consumption.
Alcohol— Alcoho l consumpt ion is not allowed from 12 hours prior to all study  visits and during 
CRU stays.  At all other times, alcohol consumpt ion shoul d be limitedto21units per week for 
males and 14 units per week for females (1unit= 12 oz or 360 mL of beer, 5oz or 150 mL of 
wine ,1.5oz or 45 mL of dist illed spirits) .
Smoking —Subjects who sm oke shoul d maintain a stabl e smoking habi t throughout the study .  
Subjects will be asked to refrain from smoking for approximately 2 hours prior to each ECG and
vital sign m easurements as well as abide by the CRU smoking guidelines.
I6T-JE-AMAD (a)Protoco l Page 32
LY3074828Exercise —Strenuous activit y shoul d be avo ided from 24hours prior to admissio n unt il discharge 
from the CRU.
Contraception —Subjects with partners of childbearing potential must agree to use a reliable 
method of birth control during the study  and until 3months after the subject’s dose .
9.5.1. Special Treatment Considerations
9.5.1.1. Premedication for Infusions
Prem edicat ion for the infusions is not planned.  However, if an infusio n reaction occurs, 
appropriate medicat ion may be used as determined by  the study  invest igator (
s) (see Secti on9.7).  
If infusio n reactions are observed but review of the data suggests that dose escalat ion may 
continue, administration of acetaminophen 500 mgto 1000 mg,and/or an ant ihistamine, such as
diphenhydramine ( Benadryl ®),may be administered orally 30 minutes to 60 minutes prior to the 
start of infusio n for subsequent subjects.
The decisio n to implement premedicat ion for infusio ns in subsequent cohorts will be made by 
the invest igator and sponsor and recorded in th e study  docum entati on, al ong wi th the dose -
escalat ion decisio n.
Any pre medicat ions given will be documented as a concomitant therapy  (see Secti on9.7).
9.5.1.2. Management of Infusion Reactions
Due to the risk of an infusio n reaction wit h any bio logical agent , all subjects shoul d be 
monitored cl osely .  Symptom s and signs that may  occur as part of an infusio n reaction include, 
but are not limited to, fever, chills, nausea, headache, bronchospasm, hypotension, angioedema, 
throat i rritation, rash, pruritus, myalgia, and dizziness.  In the event that a significant infusio n 
reacti on occurs, the fo llowing gui dance shoul d be fo llowed:
the IPinfusion should be slowed or stopped, depending on the symptoms/signs present
oif slowed, the infusi on shoul d be com pleted at the sl ower rate, as tol erated
oif stopped, no further attempts to administer the IPwill be made
supportive care should be emplo yed in accordance with the symptoms/signs
9.6. Blinding
This is a subject -and invest igator -blind study .  The sponsor and site pharmacists will be 
unblinded .  
To preserve the blinding of the study , a minimum number of Lilly  personnel  will see the 
rando mizat ion table and treatment assign ments before the study  is complete.  The Lilly clinical 
pharmaco logist will have open access to thi s table .  Subject randomizat ion codes and drug 
accountabilit y records will be held in a secure location at the CRU, accessible only by  
individuals invo lved w ith study  drug preparation .  Individuals invo lved wit h study  drug
preparati on will not be invo lved in any clinical aspects of the study  including study  drug
I6T-JE-AMAD (a)Protoco l Page 33
LY3074828administration and AE assessments. Refer to Attachment 4 for details on the blinding/unblinding 
plan.
Emergency  codes will be available to the invest igator. A code, which reveals the treatment
group for a specific study  subject, m ay be opened du ring the study  only if the subject ’swell-
being requires knowledge o f the subject ’s treatm ent assi gnment.   
In case of an emergency , the invest igator has the sole responsibilit y for determining if unblinding 
of a subject’s treatm ent assi gnment i s warranted.   Subject safet y must always be the first 
consideration in making such a determinat ion.  If the invest igator decides that unblinding is 
warranted, the invest igator should make every effo rt to con tactthe Lilly clinical pharmaco logist 
or clinical research physician prior to unblinding a study  subject ’streatment assignment.  If a 
study  subject ’streatment assignment is unblinded, Lilly must be notified immediately.   Upon 
completion of the study , all codes m ust be returned to Lilly or its designee.
9.7. Concomita nt Therapy
Over -the-counter or prescript ion medication, including herbal medicat ions, are not permitted 
within 14 days pri or to dosing and throughout the study .  Ho wever, stable doses of oral  
contraceptive, hormone replacement therapy , or vi tamins at usual doses m ay be allowed as per 
judgment of the investigator .  Any other drugs are to be avo ided during the study  unless required 
to treat an AE.  If the need for concomitant medication arises, inclusion or continuat ion of the 
subject may be at the discret ionof the invest igator after consultation wit h a Lilly clinical 
pharmaco logist or clinical research physician . Any additional medicat ion used during the course 
of the study  must be docum ented.
I6T-JE-AMAD (a)Protoco l Page 34
LY307482810. Sample Collection and Safety Data Collection
Attachm ent 1 lists the schedule for sample collect ions in this study.
Attachm ent 2 lists the clinical laboratory tests that will be performed for this study .
Attachm ent 3 summarizes the blo od vol umes f or all  blood sam pling during the study .  
10.1. Laboratory Samples
Bloodand u rine samples will be collected to determine whether subjects meet 
inclusio n/excl usion criteria and to m onitor subject healt h at the visits and times specified in the 
Study  Schedule (Attachment 1 ).  Routine clinical laboratory tests will be analyzed by  a local 
laboratory .  
Invest igators must document their review of each laboratory  safety  report.
Samples co llected for specified laboratory tests will be destroyed wit hin 60 days of receipt of 
confirm ed test resul ts.  Tests are run and confirmed prompt ly whenever scient ifically 
appropriate.  When scientific circumstances warrant, however, it is acceptable to retain samples 
to batch the tests run, or to retain the samples until the end of the study  to confirm  that the resul ts 
are valid.  Certain samples may be retained for a longer period, if necessary, to comply wit h 
applicable laws, regulat ions, or l aboratory  certificati on standards.
10.2. Samples for Pharmacokinetic and Pharmacodynamic 
Evaluations
10.2.1. Pharmacok inetic Samples
At the visit s and t imes specified in the Study Schedule (Attachment 1 ), bloodsamples of 
approximately  2mL each will be collected to determine the serum concentrati ons of 
LY3074828 .  A maximum o f 3samples m ay be collected at addit ional time points during the 
study  if warranted and agreed upon between both the investigator and sponsor.  Instructions for 
the collect ion and handling of blood samples will be provided by the sponsor.   The actual date 
and time ( 24-hour cl ock time ) of each sampling will be recorded.
Drug concentration informat ion that wouldunblind the study  will not be reported to invest igat
ive 
sites or blinded personnel until the study has been unblinded .
10.2.2. Bioanalysis
Samples will  be analyzed at a l aboratory  approved by  the sponsor and stored at a facilit y 
designated by  the sponsor .
Concentrations of LY3074828 will be assayed using a validated enzy me-linked immunosorbent 
assay .  Analyses of samples collected from placebo -treated subjects are not pl anned.
Bioanaly tical samples collected to m easure IPconcentrations will be retained for a maximum o f 
1year fo llowing last subject visit for the study.
I6T-JE-AMAD (a)Protoco l Page 35
LY307482810.3. Samples for Biomarker Research
Biomarker research is performed to address questions of relevance to drug disposit ion, target 
engagement, pharmacodynamics, mechanism o f action, variabilit y of pat ient response (including 
safet y), and clinical outcome.  Sampl e collect ion is incorporated into clinical studies to enable 
examinat ion of these questions through measurement of bio molecules including DNA, RNA, 
proteins, lipids, and other cellular elements .
10.3.1. Samples for Genetic Biomarker Research
A blood sam ple will be collected for pharmacogenetic analysis as specified in the Study  
Schedule ( Attachment 1 ) where local regulat ions allow.
Samples will  notbe used to conduct unspecified disease or populat ion genet ic research either 
now or in the future.  Samples will be used to investigate variable response to LY3074828.  
Assessment of variable response may  include evaluati on of  AEs or differences in efficacy.
All pharm acogenet ic samples will be coded with the subject number.  These samples and any 
data generated can be linked back to the subject only by the invest igator site personnel.
Samples will  be retained for a m aximum  of 15years after the last subject visit for the study , or 
for a shorter peri od if local regulations and/or ERBs impose shorter time limits, at a facilit y 
selected by  the sponsor.  This retent ion peri od enables use of new techno logies, response to 
regul atory  questi ons, and invest igation of variable response that may not be observed unt il later 
in the development of LY3074828 or after LY3074828 beco mes co mmercially available .  
Molecular techno logies are expected to improve during the 15 -year storage period and therefore 
cannot be specifically  name d.  However, exist ing approaches include who le geno me or exome 
sequencing, geno me wide association studies, and candidate gene studies.  Regardless of 
techno logy utilized genoty ping data generated will be used only for the specific research scope 
described in this sect ion.
10.3.2. Samples for Exploratory Evaluation
Samples will  be collected for potenti al nonpharmacogenetic bio marker research where local 
regul ations allow. Samples may be used for research on IL -23, pathways associated with IL -23 
biology, mechanism of action of  LY3074828, and/or research method or in validat ing diagnostic 
tools or assay (s) rel ated to ul cerative colit is.
Who le blood mRNA, serum, and plasma will be collected at the times specified in the study  
schedule ( Attachm ent 1 ).Proteomic, gene -expressio n, geno mic, epigenet ic, or metabo lomic 
analysis may  be perform ed on these samples.
Samples will  be ident ified by the subject number (co ded) and stored for up to a maximum o f 
15years after the last subject visit for the study at a facilit y selected by  the sponsor.
I6T-JE-AMAD (a)Protoco l Page 36
LY307482810.4. Samples for Immunogenicity Research
Blood sam ples f or immunogenicit y testing will  be collected as specified in the Study  Sched ule
(Attachm ent 1 )to determine ant ibody  producti on against the IP.  Addit ional samples may be 
collected if there is a possibilit y that anAE isimmuno logically  mediated.  Immunogenicit y will 
be assessed by  a validated assay designed to detect antidrug ant ibodies in the presence o f the IP.  
Antibodies may be further characterized and/or evaluated for their abilit y to neutralize the 
activit y of the IP.  Immunogenicit y samples may  also be analyzed for LY3074828 concentrations 
to facilitate in the interpretation of immunogenicit y data.
Samples may  be stored for a m aximum of 15 years fo llowing l ast subject visit for the trial at a 
facilit y selected by  the sponsor to enable further analysis of immune responses to the IP.  The 
durati on allows the sponsor to respond to regulatory  requests rel ated to the IP.
10.5. Safety Evaluations
Invest igators are responsible for monitoring the safety of subjects who have entered this study  
and for al erting Lilly  or its designee to any  event that seems unusual, even if this event may be 
considered an unant icipated benefit to the subject .
The invest igator is responsible for the appropriate medical care of subjects during the study .  
Planned safet y assessments and measures are detailed in S ection10.5.3 , but addit ional 
assessments and safet y tests m ay be perform ed at the invest igator’s discretion.
The invest igator remains responsible for following, through an appropriate health care option, 
AEs that are serious , considered related to study  treatm ent or the study ,or that caused the subject
to discont inue before completing the study.  The subject shoul d be f ollowed unt il the event is 
resolved or explained.  Frequency o f follow-up eval uation is left to the discret ion of the 
investigator.
In addit ion to records of observat ions made at specific t imes, unexpected signs and symptoms 
and conco mitant m edicati ons will be recorded in the clinical trial records throughout the study .
10.5.1. Adverse Events
Lilly has standards for reporting AEs that are to be fo llowed regardl ess of applicable regulatory  
requi rements that m ay be less stringent.
Cases of pregnancy that occur during maternal or paternal exposures to the IPshould be 
reported.  Data on fetal outcome and breast -feeding are collected for regulatory reporting and 
drug safet y evaluat ion.
After the informed consent form ( ICF) is signed, site personnel will record any  change in the 
condi tion(s) and the occurrence and nature of any AEs.  All AEs related to protocol procedures 
are reported to Lilly or designee.
Any clinically  significant findings fro m ECGs, l aboratory  values, vital sign meas urements , and 
other procedures should be reported as an AE to Lilly  or its designee.
I6T-JE-AMAD (a)Protoco l Page 37
LY3074828In addit ion, all AEs occurring after the subject receives the first dose of the IPmust be reported 
to Lilly  or its desi gnee via CRF.
Invest igators will be instructed to r eport to Lilly or its designee their assessment of the potential 
relatedness of each AE to protocol procedure, IP, and/or drug delivery system via the CRF.
The invest igator decides whether he or she interprets the observed AEs as either related to 
disease, study  medicati on, study  procedure, or other concomitant treatment or pathologies.  To 
assess the relat ionship of the AE to the IP, the fo llowing termino logies are defined:
Related :  Adirect cause and effect relat ionship between the study  treatm ent and 
the AE i s likely.
Possibly related :  Acause and effect relat ionship between the study  treatm ent 
and the AE has not been demo nstrated at this t ime and is not probable but is also 
not impossible.
Unrelated :  Without question, the AE is definitely not associated with the study  
treatm ent.
As per Lilly’s standard operating procedures all “related” and “possibly related” AEs and SAEs 
will be defined as related to the IP.
If a subject ’s dosage is reduced or treatment is discontinued as a result of an AE, study  site 
personnel must clearly  report to Lilly or its designee via CRF the circumstances and data leading 
to any  such dosage reduction or discont inuat ion of treatm ent.
10.5.2. Serious Adverse Events
An SAE is any  AE from this study  that resul ts in one of the fo llowing outcom es:
death
initial or prolonged inpatient hospitalizat ion
a life- threatening experience (that is, immediate risk of dying)
persistent or significant disabilit y/incapacit y
congenital ano maly/birth defect
considered significant by  the invest igator for any other reason
Important m edical ev ents that may not resul t in death, be life -threatening, or require 
hospi talizati on may  be considered SAEs when, based upon appropriate medical judgment, they  
may jeopardize the subject and may require medical or surgical intervent ion to prevent one of the 
outcom es listed in this definit ion.
Planned surgeries should not be reported as SAEs unless the underlying medical condit ion has 
worsened during the course of the study .
I6T-JE-AMAD (a)Protoco l Page 38
LY3074828Study  site personnel  must al ert Lilly or i ts desi gnee of  any SAE within 24 hours of invest igator 
awareness o f the event via a sponsor -approved method.  If alerts are issued via telephone, they 
are to be immediately fo llowed wi th official  notificati on on study -specific SAE forms.  This 
24-hour notificat ion requirement refers to the init ial SAE information and all fo llow -up SAE 
inform ation.  
SAEcollect ion begins after the subject has signed informed consent and has received IP.  If a 
subject experiences an SAE after signing informed consent but prior to receiving IP, the event 
will NOT be re ported as serious unless the invest igator feels the event may have been caused by 
a protocol procedure.
SAEs occur ringup to and including the subject ’s last study visit will be co llected ,regardless o f 
the invest igator’s opinio n of causation, in the clinical data collect ion database andthe 
pharmacovigilance system at the sponsor .
The invest igator does not need to actively mo nitor subjects for AEs once the trial has ended 
unless specified in the protocol.   However, i f an investigator becomes aware of SAEs occurring 
to a subject after the subject ’s participat ion in the trial has ended , the investigator should report 
them to the sponsor, regardless of the invest igator’s opinio n of causat ion,and the SAEs will be 
entered in the pharmacovigilance system at the sponsor.
Inform ation on SAEs expected in the study  popul ation independent of drug exposure and that 
will be assessed by  the sponsor in aggregate periodically during the course of the trial may  be 
found in the IB.  
10.5.2.1. Suspected Unexpected Serious Adverse Reactions 
Suspected unexpected serious adverse react ions (SUSARs) are serious events that are not listed 
in the IB and that the investigator ident ifies as related to IPor procedure.  United States 21 
CFR 312.32 and European Unio n Clinical Trial Directive 2001/20/EC and the associated 
detailed guidances or nati onal regulatory  requi rements in parti cipat ing countries require the 
reporting of SUSARs.   Lilly has procedures that will be fo llowed for the recordin g and expedi ted 
reporting of SUSARs that are consistent with glo bal regul ations and the associated detailed 
guidances .
10.5.3. Other Safety Measures
10.5.3.1. Physical Examination
Physical examinat ions and routine medical assessments will be conducted as specified in the 
Study  Schedule and as clinically  indicated (Attachment 1 ).
10.5.3.2. Vital Signs
Blood pressure and pulse ratewillbe measured as specified in the Study  Schedule and as 
clinically indicated (Attachment 1) .
Blood pressure and pulse rate should be measured after at least 5minutes supine.
I6T-JE-AMAD (a)Protoco l Page 39
LY3074828If orthostatic measurements are required, subjects shoul d be supine for at l east 5minutes and 
stand for at least 3 minutes.
If the subject feels unable to stand, supine vital signs only will be recorded.
Unscheduled orthostatic vital signs should be assessed, if possible, during any AE of dizziness or 
posture -induced symptoms.  Addit ional vital signs may be m easured during each study  period as 
per judgment of the invest igator .
Body  temperature (oral)will be measured as specified in the Study  Schedule and as clinically 
indicated (Attachment 1).
10.5.3.3. Body Weight and Height
Body  weight will be recorded as specified in the Study Schedule and as clinically indicated 
(Attachm ent 1 ).  Height will be m easured only  at screening; subject is to remove shoes.
10.5.3.4. Electrocardiograms
For each subject , 
a 12-lead digital electrocardiogram (ECG) will be collected as replicates 
(triplicates) except for screening visit according to the Study  Schedule (Attachm ent 1 ).  
Electrocardiograms must be recorded before collecting any blood for safety or PKtests.   
Subjects must be supine for at least5 minutes befo re ECG collect ion and rem ain supine but 
awake during ECG collect ion.  Consecutive replicate ECGs will be obtained at approximately 
1-minute intervals.  Electrocardi ogram s may  be obtained at addit ional times ,when deemed 
clinically necessary .  
Collection of additional ECGs at a particular time point is allowed to 
ensure high -qualit y records.
Electrocardiograms will be interpreted by  a qualified physician ( the investigator or qualified 
designee ) at the si te as soon after the time of ECG collect ion as possible and ideally  while the 
subject is still present to determine whether the subject meets entry criteria at the relevant visit(s) 
and for immediate subject management, should any clinically rel evant findings be identified.
If a clinically significant quantitative or qualitat ive change fro m baseline is ident ified after 
enrollment, the investigator will assess the subject for symptom s (for example, pal pitations, near 
syncope, syncope) to determine whether the subject can continue in the study .  The invest igator 
or qualified designee is responsible for determining if any change in subject management i s 
needed and must document his/her review of the ECG printed at the time of evaluat ion from at 
least 1 of the replicate ECGs fro m each time po int.
Digital ECGs will be electroni cally transmitted to a central ECG laboratory  designated by  Lilly .  
The central ECG laboratory  will perf orm a basic quali ty control  check (for example, 
demographics and study  deta ils) then store the ECGs in a database.  At a future time, the stored 
ECG data may be overread at the central ECG laboratory  for further eval uation of  machine -read 
measurements or to meet regulatory  requi rements.
The m achine -read ECG intervals and heart ra te may be used for data analysis and report writing 
purposes unless a cardi ologist overread of the ECGs is conducted prior to complet ion of the final 
study  report (in which case the overread data would be used).
I6T-JE-AMAD (a)Protoco l Page 40
LY307482810.5.4. Safety Monitoring
The Lilly clinical pharm acologist or clinical research physician /scient istwill mo nitor safet y data 
throughout the course of the study .
Lilly will review SAEs wit hin time frames mandated by co mpany procedures.  The Lilly clinical 
pharmaco logist or research physician will consul t with the f unctionally  independent Gl obal 
Patient Safet y therapeutic area physician or clinical research scient ist when appropriate and 
periodically  review:
trends in safety  data
laboratory  analy tes 
AEs including mo nitoring of incidence of and nature of any infect ions, infusio n react ions, 
and inject ion-site reacti ons
10.5.5. Complaint Handling
Lilly co llects product complaints on IPs and drug delivery  systems used in clinical trials in order 
to ensure the safet y of study  partici pants, m onitor quali ty, and to facilitate process and product 
improvements.
Com plaint s related to unblinded comparator drugs or concomitant drugs/drug delivery  system s 
are reported directly to the manufacturers of those drugs/devices in accordance with the package 
insert.
For blinded st udies, all product complaints associated with material packaged, labeled, and
released by Lilly  or its designee will be reported . 
The invest igator or his/her designee is responsible for handling the fo llowing aspects of the 
product complaint process in a ccordance wit h the instructions provided for this study :
recording a complete descript ion of the product complaint reported and any associated 
AEs using the study -specific co mplaint form s provided for this purpose
faxing the completed product complaint for m within 24 hours to Lilly or its designee
If the invest igator is asked to return the product for invest igation, he/she will return a copy  of the 
product complaint form with the product.
10.6. Appropriateness and Consistency of Measurements
For thi s study , the s afety and PK assessments are appropriate and fo llow standard practice during 
Phase 1 drug development.
10.7. Compliance
Every  attem pt will be m ade to select subjects who have the abilit y to understand and co mply 
with instructi ons.  Noncom pliant subjects may be discontinued fro m the study .  The time and day  
of drug administration willbe recorded.  Drug accountabilit y records will  be maintained by the 
study  site.
I6T-JE-AMAD (a)Protoco l Page 41
LY3074828The specificat ions in this protocol for the timings of safet yand PK sampling are given as targets 
tobe achieved within reasonable limit s.  Modificatio ns may be m ade to the time points based 
upon the safety  and PKinformat ion obtained.  The scheduled t ime points may be subject to 
minor al terati ons; however, the actual time must be correctly recorded in t he CRF.
Any major m odificat ions that might affect the conduct of the study , subject safet y, and/or data 
integrity will be detailed in a protocol amendment.
I6T-JE-AMAD (a)Protoco l Page 42
LY307482811. Sample Size and Data A nalyses
11.1. Determination of Sample Size
Up to 60subjects may be enrolledin orde r that approximately  50subjects complete the study .  It 
is intended that 10subjects (6 Japanese and 4 Caucasian) will be rando mized in Cohort 1,and 
8subjects (4 Japanese and 4 Caucasian) will be rando mized inCohorts 2, 3, 4, 5, and 6 .  
The 
sample size is customary for Phase 1 studi es evaluating safet y, tolerabilit y,and PK param eters .  
Subjects who are randomized but not administered treatment or do not provide sufficient safet y 
and/or PK data may be replaced if judged necessary  by the Lilly  clinical pharmaco logist. The 
replacement subject should be assigned to the same treatment as the discont inued subject and 
shoul d be Japanese or Caucasian to match the discontinued subject.
11.2. Data Analysis Plans
11.2.1. General Considerations
Statistical analysis o f this stu dy will be the responsibilit y ofEli Lilly and Company or its 
designee .
PKanalyses will be conducted on the full analysis set .  This set includes all data fro m all 
rando mized subjects receiving at least one dose of the IPaccording to the treatm ent the subjects
actually received.  Safet y analyses will be conducted for all enrolled subjects , whether or not 
they com pleted all protocol requirements.
Addit ional exploratory  analyses of the data will be conducted as deemed appropriate.  Analyses 
will be fully detailed in the statist ical analysis plan .  Study  resul ts may  be pool ed wi th the resul ts 
of other studi es for popul ation PKanalysis purposes to avoid issues with post -hoc analyses and 
incomplete disclosures of analyses.
Data from subjects receiving placeb oin the IV cohorts will be pooled to form 1placebo group.
Data will be also summariz ed by  race (Japanese and Caucasian) where appropriate.
11.2.2. Study Participant Disposition
All subjects who discont inue from the study  will be i dentified, and the extent of their 
participat ion in the study will be reported.  If known, a reason for their discont inuat ion will be 
given.
11.2.3. Study Participant Characteristics
The subject’s age, sex, weight, BMI, height, race/subrace ,or other dem ographic characterist ics 
will be record edand summarized by treatment group as well as overall .
I6T-JE-AMAD (a)Protoco l Page 43
LY307482811.2.4. Pharmacokinetic Analyses
11.2.4.1. Pharmacokinetic Parameter Estimation
PKparameter estimates for LY3074828 will be calculated by  standard noncom partmental 
methods of analysis.
The primary  parameters for anal ysis will be C maxand AUC of LY3074828.  Other 
nonco mpart mental param eters, such as half -life, clearance, and vo lume of distribution ( apparent 
clearance and apparent volume of distribut ion for SC administration) may be reported.
11.2.4.2. Pharmacokinetic Statistical Inference
PKparameter estimates following IV administration will be evaluated to delineate effects of 
dose proportionalit y.  Log -transformed C maxand AUC estimates will be evaluated in a power 
model with log-transform ed dose as the explanatory variable .The treatment differences will be 
back-transformed to present the ratios of geo metric m eans and the corresponding 90%
confidence interval ( CI).  Exploratory  power model analysis based on the model including race 
and race -by-dose interacti on terms will be also performed to examine the effect of the race on 
dose proportionalit y.
For the SC dose, the bioavailabilit y relative to IV infusio n at the same dose will be evaluated via 
a log-transform ed m odel.  The l og-transform ed C maxand AUC will be the response variable, and 
route of administration (IV or SC) i s the explanatory  variable and rati o (SC/IV) ,and its 90% CI 
will be calculated based on the model to assess the abso lute bioavailabilit y.
11.2.5. Pharmacodynamic Analyses
Not applicabl e.
11.2.6. Pharmacokinetic/Pharmacodynamic Analyses
Not applicable.
11.2.7. Safety Analyses
11.2.7.1. Clinical Evaluation of Safety
All IPand protocol  procedure AEs will be listed, and if the frequency o f events allows, safet y 
data will be summarized using descript ive methodol ogy.
The incidence of symptoms for each treatment will be presented by  severi ty and by associ ation 
with IPas perceived by the invest igator.  Symptoms reported to occur prior to enrollment will be 
distinguished from those reported as new or increased in severi ty during the study .  Each 
symptom  will be classified by  the m ost sui table term fro m the medical regulatory  dictionary.
11.2.7.2. Statistical Evaluation of Safety
Safety param eters that will be assessed include vital signs, ECG param eters, and safet y lab 
param eters .  The parameters will be listed and summarized using standard descriptive statist ics.  
Addit ional analysis will be performed if warranted upon review of the data.
I6T-JE-AMAD (a)Protoco l Page 44
LY307482811.2.7.3. Evaluation of Immunogenicity 
The frequency of ant ibody  formati on to LY3074828 and ADA t iter will be determined.  If a 
neutralizat ion assay  is perform ed, the frequency  of neutralizing ant ibodies will be determined.  
The rel ationship between the presence (or absence) of ant ibodies and clinical parameters ( AEs,
etc.) will be assessed.  Likewise, the relationship between the presence o f antibodies and PK
param eters will  be assessed.
11.3. Interim Analyses
The Lilly study  team isunblinded.  Data may  be analyzed while the trial is ongoing ,but no 
changes to the study  design are pl anned.  An assessment commit tee will not be formed.
The first i nterim analys isis scheduled to occur when safet y and PK data through Day  15 beco me
available fromat least 8 subj ects inCohort 1including at least 3Japanese subjects on 
LY3074828 .  All safet y and PK data available from other cohorts bythis time will be included in 
the interim analysis .  The purpose of the interim analysis is to support the future inclusio n of
Japan esesubjects in Study AMAC and to determine if dose escalat ion to 1200 mg shoul d occur .
The invest igator and theLilly study  team  will review the safet y and tol erabilit y data.  The 
investigator will remain blinded and the Lilly study team will be unblinded during th isinterim 
review.
The data review for dose escalation to 2400 mg will not be included in the interim review.
An a dditional interim analys ismay occur when safety  and PK data through Day  15 beco mes 
available fro m at least 6subjects in Cohort 6, including at least 3Japanese subjects .  The purpose 
of this interim analysis is to supporta future potential higher dosage in Study AMA G.  The 
investigator and the Lilly study  team  will review the safet y and tol erabili ty data.  The 
investigator will remain blinded and the Lilly study team will be unblinded during this interim 
review.
If ADA follow
-up described in the Protocol Addendum 1 is needed for subjects in Cohort 6 , 
another interim analysis may occur when all procedures of the main protocol for Cohort 6 are 
completed, even if the ADA fo llow-up is in process .  The investigator and the L illy study  team  
will review all available data.  The investigator will remain blinded and the Lilly  study  team  will 
be unblinded during this interim review.
I6T-JE-AMAD (a)Protoco l Page 45
LY307482812. Data Management Methods
12.1. Data Quality Assurance
To ensure accurate, complete, and reliable data, Li lly or its representatives will do the fo llowing:
provi de instructi onal materi al to the study  sites, as appropriate
sponsor start -up training to instruct the invest igators and study  coordinators.  This 
training will give instructi on on the protocol, the co mpletion of the CRFs, and study  
procedures.
make periodic visit s to the study  site
be available for consultation and stay  in contact with the study  site personnel by  mail, 
telephone, and/or fax
review and evaluate CRF data and/or use standard computer edit s to detect errors in data 
collect ion
conduct a qualit y review of the database
In addit ion, Lilly or its representatives will periodically check a sample of the subject data 
recorded against source documents at the study  site.  The study  may be audi ted by  Lilly and/or 
regul atory  agencies at any  time.  Invest igators will be given notice before an audit occurs.
The invest igator will keep records of all original source data.  This might include laboratory 
tests, m edical records, and clinical notes.  If request ed, the invest igator will provide the sponsor, 
applicable regulatory  agencies, and applicable ERBs with direct access to the original source 
docum ents.
12.2. Data Capture S ystems
12.2.1. Source Data and Case Report Form
A source document is the first record of data.  Th ese can be paper ( for example, ECG tracing or 
patient diary ), a paper CRF on which the data is initially  recorded, or data captured directly on an 
investigator site electronic system ( for example, Holter monitor record data files or electronic 
healt h recor d).  The site must retain all source records and must maintain a record of any data 
where source data are direct ly entered into the paper CRF .
Data m ay then be entered into ei ther an electronic or paper CRF ,and the process will be 
docum ented and communicated by  the sponsor to the invest igator si te before first patient visit.
Some invest igator site data may be co llected directly in the paper CRF whereas other data that is 
collected by  thesite 
on paper or ele ctroni c records may be transferred to the paper CRF.
Lilly does not allow direct source data entry  into Lilly  com puter sy stems, wi th the except ion of 
the invest igator site systems at the Lilly clinical research unit.
I6T-JE-AMAD (a)Protoco l Page 46
LY3074828For data handled by a data management T PO, CRF data and some or all data that are related will 
be managed and stored electronically in the TPO system.  Subsequent to the final database lock, 
validated data will be transferred to the sponsor.
For data handled internally, CRF data and some or all data that are related will be managed by 
the sponsor and stored electronically in the sponsor’s system.
12.2.2. Ancillary Data
Data m anaged by  a central  vendor will be stored electronically in the central laboratory’s 
database system.  Data will subsequent ly be transferred from the central  vendor to the Lilly 
generic labs system and the TPO’s system.
Bioanaly tical data will  be stored electronically in the bioanaly tical laboratory ’s database.  Data 
will subsequently be transferred fro m the bioanaly tical laboratory  to the Lilly  generi c labs 
system  and the TPO’s system.
ECGdata will be stored electronically in the central database system of Lilly’s central review 
organi zation.  Data will subsequent ly be transferred fro m the central  review organizat ion system 
to the L illy generic labs system and the TPO’s system.
Data from co mplaint forms submitted to Lilly will be encoded and stored in the global product 
complaint m anagement sy stem .
I6T-JE-AMAD (a)Protoco l Page 47
LY307482813. Informed Consent, Ethical Review, and Regulatory
Considerations
13.1. Informed Consent
The i nvest igator is responsible for ensuring that the subject understands the potential risks and 
benefits of part icipating in the study, including answering any questions the subject may have 
throughout the study  and sharing in a timely manner any  new informat ion that m ay be rel evant to 
the subject’s willingness to con tinue his or her participat ion in the trial.
The ICF will be used to explain the potential risks and benefits of study participat ion to the 
subject in simple terms before the subject is entered into the study  and to document that the 
subject is satisfied with his or her understanding of the potential risks and benefits o f 
participat ing in the study and desires to particip ate in the study .
The invest igator is ult imately responsible for ensuring that informed consent is given by each 
subject before the study is started.  This includes obtaining the appropriate signatures and dates 
on the ICF prior to the performance of any p rotocol  procedures and pri or to the administration of 
the IP.
13.2. Ethical Review
Lilly or i ts representatives must approve all ICFs before they  are used at invest igative sites.  All 
ICFs must be compliant with the International Conference on Harmonisat ion of T echnical 
Requi rements for Registration of Pharmaceut icals for Hum an Use (ICH) guideline on GCP.
The invest igator must give assurance that the ERB was properly const ituted and convened as 
requi red by ICH gui delines and other applicable laws and regulations.
Docum entati on of  ERB approval  of the protocol and the ICF must be provided to Lilly  before the 
study  may begin at the investi gative si te.  The ERB(s) will review the protocol as required.
The study  site’s ERB(s) shoul d be provided wi th the f ollowing:
the current IB and updates during the course of the study
ICF
relevant curri cula vi tae
13.3. Regulatory Considerations
This study  will be conducted in accordance wit h:
1) consensus ethics principles derived fro m internati onal ethics gui delines, including the 
Declaration of Helsinki and Council forInternational Organizat ionsofMedical Sciences
(CIOMS ) Internati onal Ethical  Guidelines 
2) ICH GCP Guideline (E6)
3) applicable laws an d regulat ions
I6T-JE-AMAD (a)Protoco l Page 48
LY3074828The investigator or designee will prompt ly submi t the protocol  to applicable ERB(s).
Some of the obligat ions of the sponsor will be assigned to a TPO.
An identificat ion code assigned by the invest igator to each subject will be used in lieu o f the 
subject’s name to protect the subject’s ident ity when reporting AEs and/or other trial -related 
data.
13.3.1. Investigator Information
Site-specific contact informat ion may be provided in a separate document.
13.3.2. Protocol Signatures
The spo nsor’s responsible medical o fficer will approve the protocol, confirming that, to the best 
of his or her knowledge, the protocol accurately  describes the pl anned design and conduct of the 
study .
After reading the protocol, each principal invest igator will sign the protocol signature page and 
send a copy  of the signed page to a Lilly representative.
13.3.3. Final Report Signature
The invest igator or designee will sign the clinical study report for this study, indicat ing 
agreem ent wi th the analyses, results, and conc lusions of the report.
The sponsor’s responsible medical o fficer andstatisti cian will sign/approve the final clinical 
study  report for this study , confirming that, to the best of his or her knowledge, the report 
accurately describes the conduct and result s of the study.
I6T-JE-AMAD (a)Protoco l Page 49
LY307482814. References
Adedoku n OJ, Xu Z, Gasink C, Friedman J, Szapary  P, Lang Y, Johanns J, Gao L -L, Miao Y, 
Davis H, Hanauer S, Feagan B, Sandborn W . Pharmacokinet ics and exposure- response 
relationships o f intravenously administered ustekinumab duri ng induction treatment in pat ients 
with Crohn’s disease: results fro m the UNITI -1 and UNITI -2 studies. Oral presentation a t: 
11th Congress of European Crohn’s and Co litis Organisation (ECCO): Inflammatory  Bowel  
Diseases; Mar 16 -19, 2016; Amsterdam: The Net herlands. Oral  presentati on (OP) 028.
Andersson A, Kokkola R, Wefer J, Erlandsson -Harris H, Harri s RA. Different ial macrophage 
expressio n of IL -12 and IL -23 upon innate immune activat ion defines rat autoimmune 
suscept ibilit y. J Leukoc Biol. 2004;76(6):1118- 1124.
Cornelissen F, Asmawidjaja PS, Mus AM, Corneth O, Kikly K, Lubberts E. IL -23 dependent and 
independent stages of experimental arthrit is: no clinical effect of therapeutic IL -23p19 
inhibit ion in co llagen -induced arthrit is. PLoS One . 2013;8(2):e57553.
Croxford AL, Kulig P, Becher B. IL -12-and IL -23 in healt h and disease. Cytokine Growth Factor 
Rev. 2014;25(4):415 -
421.
El-Bassat H, Ali LA, El  Yam any S, Al  Shenawy  H, Al  Din RA, Taha A. Interleukin 23 P 19 
expressio n in pat ients with ulcerat ive co litis and its rel ation to di sease severi ty. J Mol  Biomark 
Diagn. 2014;5( 5):1000191.
Feaga n BG, Sandborn W, Panés J, Ferrante M, Louis E, 
D’Haens GR, Franchimo nt D, Kaser A, 
Dewi t O, Sei dlerU, Kim K-J, Neurath M, Scholl P, Vi svanathan S, Padul aS, Herichova I, 
SoaitaA, Hall D, Böcher WO. Efficacy and safet y of induct ion therapy  with the select ive IL -
23 inhibitor BI 655066, in patients with moderate -to-severe Crohn’s disease: results of a 
rando mized, double -blind, placebo -controlled Phase II study . Gastroenterol ogy. 2016;150(4) 
suppl  1:S1266. Abstract 812a.
Gheita TA, El Gazzar II, El -Fishawy HS, Aboul -Ezz MA, Kenawy  SA. Involvement of IL -23 in 
enteropathic arthrit is pat ients with inflammatory  bowel  disease: preliminary  resul ts. Clin 
Rheumatol. 2014;33(5):713-717.
Globig AM, Hennecke N, Martin B, Seidl M, Ruf G, Hasselblatt P, Thimme R, Bengsch B. 
Com prehensive intestinal T helper cell profiling reveals specific accumulation o f IFN-+IL-
17+coproducing CD4+ T cells in active inflammat ory bowel  disease. Inflamm Bowe l Dis. 
2014;20(12):2321 -2329.
Kopp T, Riedl E, Bangert C, Bowman EP, Greisenegger E, Horowitz A, Kittler H, Blumenschein 
WM, McClanahan TK, Marbury T, Zachariae C, Xu D, Hou XS, Mehta A, Zandvliet AS, 
Montgomery D, van Aarle F, Khalilieh S. Clinical improv ement in psoriasis wit h specific 
targeting of interleukin -23. Nature . 2015 ;521(7551) :222-226.
Krueger JG, Ferris LK, Menter A, Wagner F, Whit e A, Vi svanathan S, Lal ovic B, Aslanyan S,  
Wang EE, Hall D, Solinger A, Padula S, Scholl P.  Anti –IL-23A mAb BI 655066 for treatment 
of moderate -to-severe psoriasis: safety, efficacy, pharmacokinet ics, and bio marker results of a 
single
-rising-dose, randomized, double -blind, pl acebo -controlled trial. J Allergy Clin 
Immunol. 2015 ;136(1);116 -124.e7 .
I6T-JE-AMAD (a)Protoco l Page 50
LY3074828Monteleone I, P allone F, Monteleone G. Interleukin -23 and Th17 cells in the control of gut 
inflammat ion. Mediators Inflamm . 2009 ;2009 :297645.
Oppm ann B, Lesley R, Blo m B, Timans JC, Xu Y, Hunte B, Vega F, Yu N, Wang J, Singh K, 
Zonin F, Vaisberg E, Churakova T, Liu M, Go rman D, Wagner J, Zurawski S, Liu Y, Abrams 
JS, Moore KW, Rennick D, de Waal -Malefy t R, Hannum C, Bazan JF, Kastelein RA. Novel 
p19 protein engages IL -12p40 to form a cy tokine, IL -23, wi th biological act ivities similar as 
well as dist inct fro m IL-12. Immun ity. 2000;13(5):715 -725.
Ordás I, Mould DR, Feagan BG, Sandborn WJ. Anti -TNF m onocl onal antibodies in 
inflammatory  bowel  disease: pharmacokinet ics-based dosing paradigms. Clin Pharmaco l Ther . 
2012;91(4):635 -646.
Ruutu M, Thomas G, Steck R, Degli- Espost i MA, Zinkernagel MS, Alexander K, Velasco J, 
Strutton G, Tran A, Benham H, Rehaume L, Wilson RJ, Kikly K, Davies J, Pettit AR, Brown 
MA, McGuckin MA, Tho mas R. β -glucan tri ggers spondylarthrit is and Crohn's disease -like 
ileitis in SKG mice. Arthri tis Rheum . 2012;64(7):2211 -2222.
Sandborn WJ, Gasink C, Gao LL, Blank MA, Johanns J, Guzzo C, Sands BE, Hanauer SB,
Targan S, Rutgeerts P, Ghosh S, de Villiers WJ, Panaccione R, Greenberg G, Schreiber S,
Lichtiger S, Feagan BG; CERTIFI Study  Group. Ustekinumab induct ion and m aintenance
therapy  in refractory  Crohn’s disease. N Engl J Med . 2012;367(16):1519 -1528.
Sands BE, Chen J, Penney M, Newho ld P, Faggioni R, van der Merwe R, Patra K, Klekotka P, 
Pulkstenis E, Drappa J, Gasser RA Jr. A rando mized, double -blind placebo -controlled phase 
2a induct ion study  of MEDI2070 (ant i-p19 ant ibody) in patients with active Crohn’s disease 
who have failed ant i-TNF ant ibody  therapy . J Crohns Co litis. 2015;9(suppl 1):S15 -S16.
Sofen H, Smit h S, Matheson RT, Leonardi CL, Calderon C, Brodm erkel  C, Li  K, Campbell  K, 
Marciniak SJ Jr, Wasfi Y, Wang Y, Szapary  P, Krueger JG. Guselkumab (an IL -23-specific 
mAb) demonstrates clinical and mo lecular response in patients with moderate -to-severe 
psori asis. J Allergy  Clin Immunol . 2014;133(4): 1032-1040.
Stelara (ustekinumab )[package insert]. Horsham, PA: Janssen Biotech Inc; 2013.
Toussirot E, Michel F, Béreau M, Binda D. Ustekinumab in chronic immune -mediated diseases: 
a review of long term safet y and patient improvement. Patient Prefer Adher ence. 
2013;7:369 -
377.
Yarur AJ, Abreu MT, Deshpande AR, Kerman DH ,Sussman DA. Therapeut ic drug monitoring 
in patients with inflammatory  bowel  disease. World J Gastroenterol . 2014;20 (13):3475 -3484.
I6T-JE-AMAD (a)Protoco l Page 51
LY3074828Attachment 1. Protocol AMADStudy Schedule
I6T-JE-AMAD (a)Protoco l Page 52
LY3074828Study Schedule Protocol I6T-JE-AMAD
Study DayScreening
28 days –2 –1 1 2 4 8 11 a 15 22 29 43 57 71 85 ED
Visit Window ± 1d± 1d± 1d± 2d± 2d± 2d± 3d ± 3 d ± 3d±3d
Informed consent X
Admission to CRU X
Discharge from CRU X
Review/confirm I/E criteria X X
Complete medical history X
LY3074828 or placebo 
administrationX
Weight X X X X X
Height X
Complete physical examination X X X X
Directed physical examination X X X X X X X X X X
Chest x -ray X
Concomitant medications X X X X X X X X X X X X X X X
Review preexisting 
conditio ns/AEsX X X X X X X X X X X X X X X
Vital signs ( pulse rate, blood 
pressure, and temperature) b,cX0, EI d, 
2e, 60, EI d, 
2e, 624 72 168 240 336 504 672 1008 1344 1680 2016 X
12-lead ECGs c,fX0, EI d, 
2e, 60, EI d, 
2e, 624 72 168 240 336 504 672 1008 1344 1680 2016 X
Laboratory Tests
QuantiFERON -TB Gold or TST X
HIV/HBV/HCV testing X
FSH g X
Serum pregnancy testg X
Urine pregnancy testg X X X X X
Serum chemistry ,hematology ,
and urinaly sis
X X X X X X X X X
Explo ratory  storage samples
(serum, plasma, RNA)X X X X X X X
Pharmacogenetics storage 
sample (DNA)X
I6T-JE-AMAD (a)Protoco l Page 53
LY3074828Study Schedule Protocol I6T-JE-AMAD
Study DayScreening
28 days –2 –1 1 2 4 8 11 a 15 22 29 43 57 71 85 ED
Visit Window ± 1d± 1d± 1d± 2d± 2d± 2d± 3d ± 3 d ± 3d±3d
Immunogenicity X X X X
LY3074828 (PK) 
concentration h0, EI d, 
2e, 624 72 168 240 336 504 672 1008 1344 1680 2016 X
Abbreviations:   0 =predose ;AE=adverse event; CRU = clinical research unit; d =day; DNA =deoxyribonucleic acid; ECG =electrocardiogram; ED =early 
discontinuation; EI=end of infusion; FSH =follicle -stimulating hormone; HBV =hepatitis B virus; HCV =hepatitis C virus ; HIV =human 
immunodeficiency virus; I/E =inclusion/exclusion; IL =interleukin; lab =laboratory; PK =pharmacokinetic ; TST = tuberculin skin test .
aDay 11required for subjects receiving subcutaneous dosing only.
bVital signs should be taken following an approximate 5 -minute rest in supine position. Vital signs on days without dosing should be taken close to the Day 1 
dosing time where possible .
cTime from starting infusion in hours, with the exception of Day –1.  Time - matched ECGs and vital signs on Day –1 should approximately match the times 
planned on Day 1.  Vital signs and ECG recording should occur prior to PK sampl ing, except at the end of infusion, at w hich time PK sampling will occur 
first.
dRequired for intravenous cohorts only .  
PK samples will be collected precisely at end of infusion.  V ital signs and ECG sshould be taken approximately 
10minutes after the end of infusion.
eNot done for Coho rt3.
fECGs should be taken after an approximate 5
-minute rest in supine position. ECGs on days without dosing should be taken close to the Day 1 dosing time , 
where possible .ECGs will be collected in triplicate except for screening visit.
gAll female subjects of childbearing potential will have serum pregnancy test at screening.  For women who are considered to be postmenopausal, FSH should 
be drawn to confirm postmenopausal status as defined in inclusion criterion [1 b] and to be considered exempt for further pregnancy tests during the study.
hTime from starting infusion in hours.  Samples are requested to be taken at the specified time and on days without dosing should be taken close to the Day 1 
dosing time where possible .  Actual times of doses and samples are to be recorded accurately to the minute on the appropriate forms.
I6T-JE-AMAD (a)Protoco l Page 54
LY3074828Attachment 2. Protocol AMADClinical Laboratory  Tests
Laboratory Tests 
Hematology: a Clinical Chemistry a
Hematocrit Sodium
Hemoglobin Potassium
Erythrocyte count (RBC) Calcium
Mean cell volume Glucos e fasting
Mean cell hemoglobin Blood urea nitrogen (BUN)
Mean cell hemoglobin concentration Uric acid 
Leukocytes (WBC) Total cholesterol
Cell Morphology Total protein
Absolute counts of: Albumin
Neutrophils Total bilirubin
Lymphocytes Alkaline phosphatase
Monocytes Aspartate aminotransferase (AST)
Eosinophils Alanine aminotransferase (ALT)
Basophils Creatinine
Platelets
Urinalysis a Ethanol testing c,d
Specific gravity Urine drug screen c,d
pH Hepatitis B surface antigen c
Protein Hepatitis B cor e antibody c
Glucose Hepatitis C antibody c
Ketones HIV antibodies c
Bilirubin Pregnancy test (serum aand urine)
Urobilinogen FSH c
Blood QuantiFERON -TB Gold test a,c
Nitrite
Microscopic examination of sediment b
Abbreviations:  FSH =follicle -stimulating hormone; HIV =human immunodeficiency virus; RBC =red blood cells; 
WBC =white blood cells.
aResults will be validated by the local laboratory at the time of initial testing .
bTest only if dipstick result is abnormal.
cPerformed at screening only .
dUrine drug screen and ethanol level may be repeated prior to admission to the clinical research unit as per 
judgment of investigator.
I6T-JE-AMAD (a)Protoco l Page 55
LY3074828Attachment 3. Protocol AMADBlood Sampling Summary
This table summarizes the approximate number of venipunctures and blood volumes for all 
blood sam pling (screening, safet y laboratori es,and bioanaly tical assays) during the study .  Fewer 
venipunctures and blood draws may actually occur, but this will not require a protocol 
amendment.
Protocol I6T-JE-AMAD Sampling Summary
PurposeMaximum Blood Volume 
per Sample (mL)Maximum Number 
of Blood SamplesMaximum Total 
Volume (mL)
Screening tests a 45 1 45
Clinical laboratory tests a 12.5 7 87.5
Pharmacokinetics 2 15+3 36
Immunogenicity 10 3 30
Pharmacogenetics 10 1 10
Explo ratory  storage samples 
(serum, plasma, RNA)14.5 6 87
Total 295.5
Total for clinical purposes 300
aAdditional samples may be drawn if needed for safety purposes.
I6T-JE-AMAD (a)Protoco l Page 56
LY3074828Attachment 4. Protocol AMADBlinding /Unblinding Plan 
Levels of unblinding are indicated in the table belo w. This table provi des general  guidance as to
who will be allowed access to rando mizat ion codes at various steps of the trial. The informat ion 
in the protocol will always take precedence over this table.  For interim analysis (IA), 
appropriate IA team members , including stati stician, programmer, and data manager will be 
ident ified and agreed upon between Lilly and the TPO .  
Randomization data are kept strict ly confident ial and are accessible only by  authori zed personnel 
until unblinding of the tr ial as described below.   All measures possible must be taken to maintain 
the blind ,which means that access to the rando mization code must be restricted to authorized 
personnel as described in the protocol and summarized in the tabl e bel ow.
If there is a need for unblinding of select people from Lilly and/or the TPO who are not dealing 
with the si te, the detailed process including formation of the unblinded team, creating restricted 
access electronic fo lders, and measures taken to gu ard against inappropriate disseminat ion of 
treatm ent codes ( for example, by maintaining no contact with the study  team  until team is 
unbli nded) will be described in the unblinding plan or another appropriate document and 
approval  sought from  Lilly and Cova nce team  statisti cians.
I6T-JE-AMAD (a)Protoco l Page 57
LY3074828Study I6T-JE-AMAD Blinding and Unblinding Plan
Study Timelines
Study Team Member Screening RandomizationTreatment 
Phase Follow -UpDatabase 
Lock
General
Drug supply NA U U U U
Randomization statisticians NA U U U U
ECG r eader (if read later) NA B B B B
BioAnalysis lab/sample analysis NA U U U U
Clinical Site
Pharmacist NA U U U U
Dosing staff NA B B B B
Subject NA B B B B
Investigator NA B B B B
Study monitor NA U U U U
Covance/CDARO
Project integration NA U U U U
Data management NA U U U U
Programming NA U U U U
Statistic ian NA U U U U
Medical writing NA U U U U
Pharmacokinetic scientist /associate NA U U U U
Lilly
BioPharm coordinato r NA U U U U
CPA NA U U U U
DSA NA U U U U
SDTM core team NA U U U U
Statistic ian NA U U U U
Medical writing NA U U U U
Clinical pharmacologist NA U U U U
Pharmacokinetic scientist /associate NA U U U U
Abbreviations:  B = blinded; CPA = clinical pharmacology associate; DSA = data sciences associate; ECG = 
electrocardiogram; NA=not applicable; SDTM = study data tabulation model; U = unblinded .
I6T-JE-AMAD (a)Protoco l Page 58
LY3074828Attachment 5. Protocol A mendment I6T -JE-AMAD(a)
Summary : A Single -Dose Study  to A ssess the Safety , 
Tolerability , and Pharmacokinetics of LY3074828 in 
Japanese and Caucasian Healthy  Subjects
Overview
Protocol  I6T-JE-AMAD ,A Single -Dose Study  to Assess the Safet y, Tolerabilit y, and 
Pharmacokinet ics of LY3074828 in Japanese and Caucasian Healt hy Subjects ,has been 
amended .The new protocol is indicated by  Amendm ent(a) and will be used to conduct the 
study  in place of any preceding versio n of the protocol.
The overall changes made to this protocol aredue to the implement ation of Cohort 6 ,which 
contains the addit ional higher dose of 2400 m g IV,which will be the new maximum dose in the 
study . Editorial changes and form atting correcti ons were made throughout the protocol, but not 
necessarily documented below. The rationale for the changes is as fo llows:
The original protocol  assesses the safet y, tolerability , and pharmacokinetic profile up to 1200 mg 
IV of LY3074828 in Japanese and Caucasian healthy subjects . Single doses of up to 1200 mg IV 
support the highest dose of 1000 mg IV in Phase 2 studies forpatients with ulcerative colit is 
(Study  AMAC) a nd Crohn’s disease (Study AMAG) ,in that the safet y data to date does not 
reveal any  dose-related safety  or tol erabili ty issues with dose regimens of up to 1000 mg IV 
Q4W for up to 52 weeks .
Dose l evels higher than 1000 mg may be required to suppor t the best clinical outcomes in many 
auto-inflammatory disease indicat ions, including IBD. Study  20029153 ( 4-week repeat -dose 
monkey study ) showed the m argin o f safety  for2400 mg IV to be 1. 9
-fold. This value is based 
on the predicted exposure at 2400 m g in humans after a single dose compared to the observed 
exposure at 100 mg/kg IV, administered once weekly in monkeys.  In thi s study , 100 mg/kg , the 
highest dose tested, was the NOAEL.
The 2400- mg IV dose was selected to support potent ial future studi es in pat ients with ulcerative 
colitis and Crohn’s disease, where high erIV doses (potentially beyo nd 1200 mg) during 
induct ion treatment may  be requi red to m aximize efficacy . Because the drug is degraded via the 
catabolic pathway (same as IgG) and the amount of drug is much smaller than the endogenous 
IgG in the body , it is unlikely that an unexpected PK profile will be observed after implement ing 
a 2400 -mg IV dose. 
I6T-JE-AMAD (a)Protoco l Page 59
LY3074828The overall changes and rationale for the changes made to this protocol are descri bed in the 
following table:
Amendment Summary for Protocol I6T -JE-AMAD Amendment (a)
Section # and Name Description of Change Brief Rationale
Cover page Approval date removed New date will be timestamped 
upon approval of protocol 
amendment
Cover page Cohort 6 added with 2400 -mg 
dosageSingle doses of up to 
1200 mg IV to date did not 
reveal any  safety  or 
tolerability issues. 
Dose levels higher than 
1000 mg may be required to 
support the best clinical 
outcomes in many auto -
inflammatory disease 
indicatio ns, including IBD.
Because the drug is 
degraded via the catabolic 
pathway (same as IgG) and 
the amount of drug is much 
smaller than the endogenous 
IgG in the body, it is 
unlikely  that an unexpected 
PK profile will be observed 
after implementing a 
2400 -mg IV dose. 2. Sy nopsis, Number of 
Planned SubjectsNumber of planned subjects
increased from 42 to 50
2. Sy nopsis, Study Design Cohort 6 added with 2400 -mg 
dosage
2. Sy nopsis, Investigational 
Product, Dosage, and Mode of 
Administration  Cohort 6 added with 2400 -mg 
dosage
2. Sy nopsis: Evaluation 
MethodsCohort 6 added (n=8) ; number of 
planned subjects completing study 
increased from 42 to 50; 
added information regarding a 
possible interim analysis for 
Cohort 6 subjects
Table of Contents: List of 
Attachments , Attachment 5Protocol amendment section added Added as per template
5.1 General Introduction Updated per IB Consistent with IB
7.1. Summary of Study Design Cohort 6 added; both Cohorts 5 
and 6 will be dosed after 
confirming the safety and PKfrom 
Cohort 1 and Cohort 5, 
respectivelySingle doses of up to 1200 
mg IV to date did not reveal 
any safety  or tolerability  
issues. 
Dose levels higher than 
1000 mg may be required to 
support the best clinical 
outcomes in many auto -
inflammatory diseas e 
indications, including IBD.
Because the drug is 
degraded via the catabolic 
pathway (same as IgG) and 
the amount of drug is much 
smaller than the endogenous 
IgG in the body, it is 
unlikely  that an unexpected 7.1. Summary of Study 
Design, Figure AMAD.2. 
Study design for Protocol I6T 
JE AMAD.Cohort 6 added with details 
7.1. Summary of Study 
Design; TreatmentCohort 6 description added, safety 
and PK assessment added between 
Cohort 1 and 5, then 5 and 6
7.2.Discussion of Design and 
ControlCohort 6 2400 -mg dosage added
8.1.1. Inclusion Criteria Cohort 6 added to Exclusion 
Criterio n [5]
9.2. Treatment Administration; New column added to table with 
I6T-JE-AMAD (a)Protoco l Page 60
LY3074828Table AMAD. 1. Cohort 6 description PK profile will be observed 
after implementing a 
2400-mg IV dose. 9.3. Rationale for Selection of 
DoseCohort 6 description added, safety 
and PK assessment added between 
Cohort 1 and 5, then 5 and 6
9.3. Rationale for Selection of 
Dose, Table AMAD .2Cohort 6 added, paragraphs moved 
within this same section and added 
to for readability . Table AMAD. 2
updated with 2400 -mg dosing 
information
9.4. Dose Escalation Cohort 6 description added, safety 
and PK assessment added between 
Cohort 1 and 5, then 5 and 69.4.1. Dose Escalation Method
11.1. Determination of Sample 
SizeCohort 6 added , sample size 
increased from 42 subjects to 
50subjects
11.3 Interim Analyses Interim analysis information added 
for Cohort 6Cohort 6 added 
14. References References added References added to reflect 
higher dosing
I6T-JE-AMAD (a)Protoco l Page 61
LY3074828Revised Protocol Sections
Note: Deletions have been ident ified by strikethroughs .
Addit ions have been identified by  the use of underscore .
Amendment Summary for Protocol I6T-JE-AMAD Amendment (a)
Section # and Name Additions and Deletions
Cover page The study  will consist of 5 6planned dose cohorts:  4 5
intravenous cohorts (60 mg, 200 mg, 600 mg, and1200 mg ,
and 2400 mg ) 
Cover page Approval Date: 11 -Aug -2015 GMT
2. Sy nopsis, Number of Planned 
Subjectsapproximately 4250
2. Sy nopsis, Study Design The study  will consist of 5 6planned dose cohorts:  4 5IV 
cohorts (60 mg, 200 mg, 600 mg, and 1200 mg, and 2400 
mg) and 1 SC cohort (200 mg).  
2. Sy nopsis, Investigational Product, 
Dosage, and Mode of Administration  A single dose of LY3074828 will be administered IVat the 
planned dose levels of 60mg, 200 mg, 600 mg, and 1200 mg, 
and 2400 mg .  
2. Sy nopsis: Evaluation Methods Up to 60subjects may be enrolled in order that approximately 
42 50 subjects complete the study.  It is intended that 10 
subjects (6 Japanese and 4 Caucasian) will be randomized in 
Cohort 1, and 8 subjects (4 Japanese and 4 Caucasian) will be 
randomized in Cohorts 2, 3, 4,5, and 56. 
…
The first iInterim analy sis is scheduled to occur when safety 
and PK data through Day 15 become available from at least 
8subjects in Cohort 1,including at least 3 Japanese subjects 
on LY3074828 .  An a dditional interim analy sismay occur 
whensafety and PK data through Day 15 becomes available 
from at least 6subjects in Coho rt6, including at least 
3Japanese subjects on LY3074828. 
Table of Contents: List of Attachments , 
Attachment 5List of Attachments 
Attachment 5. Protocol Amendment I6T-JE -AMAD 
Summary: A Single -Dose Study to Assess the Safety, 
Tolerability, and Pharmacokinetics of LY3074828 in 
Japanese and Caucasian Healthy Subjects…..58
5.1 General Introduction …
The first such biologic to demonstrate clinical benefit in 
autoimmune disease was ustekinumab, which is now an 
approved medicine for the treatment of patients with psoriasis 
and psoriatic arthritis (Stelara package insert, 2013) and is 
being evaluated in P hase 3 trials for treatment of CD 
(Toussirot et al. 2013).   
...
One study, Study I6T -MC -AMAA (AMAA): A Phase 1, 
Randomized, Placebo -Controlled Study of LY3074828, an 
Anti-IL -23 Humanized Antibody in Subjects With and 
I6T-JE-AMAD (a)Protoco l Page 62
LY3074828Without Psoriasis, has been completed conducted to 
dateevaluating .  This study evaluated LY3074828 in healthy 
volunteers and in subjects with plaque psoriasis.  
...
No deaths , serious adverse events (SAEs), or 
discontinuations due to an adverse event (AE) were 
reported.  
Preliminary data fro m subjects administered single 
doses of up to 600 mg IV indicate that LY3074828 
has linear pharmacokinetics (PK), a low IV 
clearance (approximately 0.02 L/h), and long half -
life (~10 days), all of which are consistent with 
expectations for a monoclonal ant ibody.  SC 
bioavailability was 40% to 50%.
Treatment -emergent antidrug antibodies (ADAs) 
developed in 3 subjects after administration of single 
IV doses of LY3074828, (120 mg, 2 subjects; 350 
mg, 1 subject).  No subject had ADAs after SC 
administration.  T here was no correlation between 
ADA titers and the doses of LY3074828.
There have not yet been any studies conducted for 
LY3074828 with efficacy as a primary objective.  
However, Following single IV doses of LY3074828 
in Study AMAA, the area under the cur ve (AUC) 
and maximum drug concentration ( Cmax)increased in 
approximately a dose-proportional manner.  The 
mean terminal phase half -life across all IV doses 
was 10.5 days and did not appear to be dependent on 
dose, and the mean clearance is within the range 
expected for human monoclonal antibodies.  The 
overall mean clearance across al l doses following IV 
administration was approximately 0.526 L/day and 
is within the range expected for human monoclonal 
antibodies.  Maximum concentrations were observed 
3 day s postdose following SC administration.  Based 
on the AUC, the SC bioavailability was 40% relative 
to IV administration.
Immunogenicity evaluations were performed in 
Study AMAA.  Blood samples to evaluate anti-drug 
antibodies ( ADA) were collected at baseline and 
approximately 22, 43, and 85 days postdose.  ADA 
data were available for 45 subjects, 38 who received 
LY3074828 and 7 w ho received placebo.  All 
subjects who received placebo were ADA negative 
at baseline and postbaseline.  Only one subject who 
received LY3074828 was positive at baseline.  
Thirty- one subjects who received LY30 74828 
I6T-JE-AMAD (a)Protoco l Page 63
LY3074828(81.6%) were negative at all postbaseline time points 
evaluated.  Seven subjects who received LY3074828 
had a postbaseline positive titer; however, only 3 of 
those subjects (7.9% of LY3074828 -treated 
individuals) developed treatment -emergent ADA, 
defined as a 4-fold or greater change in titer from 
baseline.  None of these cases of treatment -emergent 
anti-drug antibodies (TE -ADA) were associated with 
treatment -emergent adverse events (TEAEs).
…
Phase 2 studies investigating the efficacy of LY3074828 as a 
potential treatment for psoriasis (AMAF), ulcerative colitis 
(AMAC), and Crohn’s disease (AMAG) are currently 
ongoing.   However, Iin Study AMAA , clinical activity was 
explored…
…
Information on AEs expected to be related to the IP may be 
found in Sectio n 7 6(Development Core Safety Information) 
of the IB.   
7.1. Summary of Study Design Subjects will be randomized to LY3074828 or placebo within
1 of 56cohorts, as shown in Figure AMAD.2.
…
Cohorts 2 through 5 6will consist of 8 subjects (4 Japanese 
and 4 Caucasian) who are randomized in a 3:1 ratio of 
LY3074828 to placebo.
…
Single doses up to 600 mg IV have been studied and shown 
to be well tolerated, therefore all cohorts, with the exception 
of Cohort 5and Cohort 6 , may  be dosed in parallel if th e site 
is able to accommodate more than 1 cohort at a time.   Cohort 
5 will be dosed after confirming the safety and PK data from 
Cohort 1.  Cohort 6 will be dosed last after confirming the 
safety and PK data from Cohort 1 5.  
7.1. Summary of Study Design, Figure 
AMAD.2. Cohort 6 added, arrow showing safety and PK assessment 
between Cohort 1 and 5, then 5 and 6
7.1. Summary of Study Design; 
Treatment…
Treatment:
…
Cohort 6: a single dose of LY3074828 2400 mg or placebo 
IV
7.2Discussion of Design and Control The dose levels included in this single -dose study are within 
the range of doses studied previously, with the exception of 
the planned 1200 mg and 2400 mgIV dose cohort , for which 
the expected exposure has an appropriate safety margin based 
on the preclinical toxicity data (see Section 9.3 for additional 
information) .
8.1.1. Inclusion Criteria [5]have a body weight of 40 .0kg or higher for Cohort s 1to4 
and 48.0 kg or higher for Cohort 5 and Cohort 6
I6T-JE-AMAD (a)Protoco l Page 64
LY30748289.2. Treatment Administration; Table 
AMAD. 1.Cohort 6, 2400 mg IV; 25 mg/mL, 96 mL
9.3. Rationale for Selection of Dose The 4 5IV doses for this study are 60, 200, 600, and1200, 
and 2400 mg and the SC dose for this study is 200 mg.
…
The low dose of 60 mg IV for this study is was chosen as one 
of the doses that was administered in the global…
...
The 200 -mgIV dose is one of the starting doses in Study 
AMAC and is one of the doses that was administered in 
Study AMAA .  It is also the SC dose that will A dose of 200 
mgSC is being administered in the maintenance period of 
Study AMAC.
The 600 -mgIV dose is the highest dose being tested in Study 
AMAC and is the highest dose that was administered in 
Study AMAA.
The original highest dose of 1200 mg, IV was tested for 
safety and tolerability , based on the safety results at each 
escalation cohort of this study. Findings from these results 
supported the highest dose of 1000 mg IV in the Phase 2 
Crohn’s disease study (Study AMAG).
The amended maximum dose of 2400 mg IV is se lected to 
support potential future studies in patients with ulcerative 
colitis and Crohn’s disease, where high IV doses (potentially 
beyond 1200 mg) during induction treatment may be required 
to maximize efficacy (Sandborn et al. 2012; Adedokun et al. 
2016 ; Feagan et al. 2016). 
The margin of safety at 2400 mg IV is 1. 9-fold .  This value is 
based on the predicted exposure at 2400 mg compared to the 
observed exposure at 100 mg/kg IV, administered once 
weekly, in the 4 -week ,repeat -dose monkey study.  In thi s 
study, 100 mg/kg was the no observed adverse -effect level 
(NOAEL )and also the highest dose tested. (see Table 
AMAD.2) .
…
Due to a lack of a preclinical disease model, the anticipated 
minimally effective dose for LY3074828 is unknown.  The 
clinical dose range for LY3074828 is not yet known, and the 
maximum planned LY3074828 dose level to be evaluated in
the Phase 2 ulcerative colitis Study AMAC is 600 mg.   
…
Therefore, this study plans plannedto evaluate the safety, 
tolerability, and PK of a 1200 -mgIV dose of LY3074828.  
Evaluatio n of this additional higher dose cohort will provide 
safety and PK data to support the use of a higher dose level in 
I6T-JE-AMAD (a)Protoco l Page 65
LY3074828later clinical development.  The 1200 -mg dose cohort (Cohort 
5) will be dosed after safety, tolerability, and PK data are 
confirmed from the 600- mg dose cohort (Cohort 1).  A 2 fold 
dose escalation will provide the most informative PK data, as 
there is minimal overlap between the 600 -mg and 1200 -mg 
doses on the basis of data obtained from simulations.  Other 
dose levels may  be dosed concurrently in this study because 
these doses have already been shown to be well tolerated in 
Study AMAA.  As shown in Table AMAD.2, the proposed 
maximum dose of 1200 mg IV infusion has a sufficient 
margin of safety both in terms of do se and exposure. The 
1200 -mg IV dose cohort (Cohort 5) was dosed after safety, 
tolerability, and PK data were confirmed from the 600 -mg 
dose cohort (Cohort 1). Other dose levels w ereasdosed 
concurrently in this study because these doses have already 
been shown to be well tolerated in Study AMAA.  Evaluation 
of 1200 -mg IV dose cohort (Cohort 5) provided safety and 
PK data to support the use of a higher dose level in Study 
AMAC and Study AMAG. 
In addition to the above evaluation, this study is amended to 
add the evaluation of safety, tolerability, and PK of a 2400 -
mg IV dose of LY3074828, since there is a possibility to 
evaluate a higher dose level up to 2400 mg IV in later clinical 
development.  The proposed dose of 2400 mg IV infusion has 
a sufficient ma rgin of safety in terms of dose.  Moreover, the 
clinical safety profile of LY3074828 available to date 
supports 2400 -mg IV administration in this study.  Single 
doses of up to 1200 mg IV were evaluated in healthy subjects 
from Study AMAD and no dose -relate d safety or tolerability 
issues were observed.  Evaluation of the safety data available 
to date in the ongoing Study AMAC and Study AMAG that 
are evaluating higher and more frequent dose regimens of up 
to 1000 mg IV Q4W for up to 52 weeks has not revealed any 
differences in the safety profile.  The PK profile of this drug 
was found to be approximately linear up to 1200 -mg IV 
administration.  Since the 2400 -mg IV dose is only 2 -fold of 
1200 mg, it is unlikely that an unexpected PK profile will be 
observed af ter administration of a 2400 -mg IV dose.  
Therefore, evaluation of this additional higher dose cohort 
(2400 mg) will provide safety and PK data to support the use 
of a higher dose level beyond 1200 mg during the clinical 
development of this compound .
9.3. Rationale for Selection of Dose, 
Table  AMAD .2[Title]: Margin of Safety for Intravenous Administration of 
1200 2400 mg
Human highest dose: ( 1200 2400 mg):
Dose: 18.5 36.9 (IV); AUC 0-672h,ss 53800 110000
I6T-JE-AMAD (a)Protoco l Page 66
LY3074828Monkey NOAELd6-month study: Dose Multiple: 5.4 2.7; 
Margin of Safety: 1.60.78
Monkey NOAELd:Dose Multiple: 5.42.7; Margin of Safety:
3.8 1.9
Footnote c: …Human AUC 0-672h,ss at 1200 2400 mgIV is 
predicted on the basis of the average IV clearance 
(0.526L/day ) observed in fromStudy I6T-MC -AMAA.  
for doses between 5 mg and 350 mg.   
9.4. Dose Escalation All doses in this study, with the exception of the 1200 -mg 
and 2400- mg dose s, have been previously tested and shown 
to be well tolerated in Study AMAA.  The only dose 
escalation decision sinthis study will be made to proceed 
from the 600-mg cohort (Cohort 1) to the 1200 -mg cohort 
(Cohort 5) and the 6001200-mg cohort (C ohort 1 5 ) to the 
1200 2400 -mg dose cohort (Cohort 5 6).  Safety and PK data 
reviewed at the time of the first interim analy sis will be used
for the escalation decision to the 1200 -mgdose. Safety and 
PK data up to the 1200 -mg dose cohort will be reviewed 
before dose escalation to 2400 mg.   
9.4.1. Dose Escalation Method …
After review of the data, an agreement on the appropriate 
dose escalation will be made by the investigator and sponsor 
for the 1200 -mg cohort (Coh ort 56).  The planned dose for 
Cohort 5 is 1200  mg, but depending on the observations 
from the 600 mg cohort (Cohort 1), the magnitude of the dose 
escalation may be reduced following data review;  the 
maximum dose for the study will be 1200  mg.  
If any of the following scenarios occur at 600 mg 
LY3074828, dose escalation to 1200  mg will not take place, 
and the dose for Cohort 5  may be reduced or the cohort will 
be canceled:
None of the following scenarios occurred at 1200 -mg 
LY3074828,
11.1. Determination of Sample Size Up to 60subjects may be enrolled in order that approximately 
42 50 subjects complete the study.  It is intended that 10 
subjects (6 Japanese and 4 Caucasian) will be randomized in 
Cohort 1, and 8 subjects (4 Japanese and 4 Caucasian) will be 
randomized in Cohorts 2, 3, 4, and5, and 6.   
11.3 Interim Analyses The first Iinterim analy sisis scheduled to occur whenwhen 
safety and PK data through Day 15 become available …
…
The data review for dose escalation to 2400 mg will not be 
included in the interim review.
An additional interim analysis may occur when safety and PK 
data through Day 15 becomes available from at least 6 
subjects in Cohort 6, including at least 3 Japanese subjects.  
The purpose of this interim analysis is to support a future 
I6T-JE-AMAD (a)Protoco l Page 67
LY3074828potential higher dosage in Study AMAG.  The investigator 
and the Lilly study team will review th e safety and 
tolerability data.  The investigator will remain blinded and the 
Lilly  study  team will be unblinded during this interim review.
If ADA follow -up described in the Protocol Addendum 1 is 
needed for subjects in Cohort 6, another interim analysis may 
occur when all procedures of the main protocol for Cohort 6 
are completed, even if the ADA follow -up is in process.  The 
investigator and the Lilly study team will review all available 
data.  The investigator will remain blinded and the Lilly study 
team will be unblinded during this interim review. 
14. References Adedokun OJ, Xu Z, Gasink C, Friedman J, Szapary P, Lang 
Y, Johanns J, Gao L -L, Miao Y, Davis H, Hanauer S, Feagan 
B, Sandborn W. Pharmacokinetics and exposure -response 
relatio nships of int ravenously administered ustekinumab 
during induction treatment in patients with Crohn’s disease: 
results from the UNITI -1 and UNITI -2 studies. Oral 
presentation a t: 11th Congress of European Crohn’s and 
Colitis Organisation (ECCO): Inflammatory Bowel Disea ses; 
Mar 16 -19, 2016; Amsterdam: The Netherlands. Oral 
presentation (OP) 028.
…
Feagan BG, Sandborn W, Panés J, Ferrante M, Louis E, 
D’Haens GR, Franchimont D, Kaser A, Dewit O, Seidler U, 
Kim K -J, Neurath M, Scholl P, Visvanathan S, Padula S, 
Herichova I, Soaita A, Hall D, Böcher WO. Efficacy and 
safety of induction therapy with the selective IL -23 inhibitor 
BI 655066, in patients with moderate -to-severe Crohn’s 
disease: results of a randomized, double -blind, placebo -
controlled Phase II study. Gastroentero logy. 2016;150(4) 
suppl 1:S1266. Abstract 812a.
…
Sandborn WJ, Gasink C, Gao LL, Blank MA, Johanns J, 
Guzzo C, Sands BE, Hanauer SB, Targan S, Rutgeerts P, 
Ghosh S, de Villiers WJ, Panaccione R, Greenberg G, 
Schreiber S, Lichtiger S, Feagan BG; CERTIFI Stu dy Group. 
Ustekinumab induction and maintenance therapy in refractory 
Crohn’s disease. N Engl J Med. 2012;367(16):1519 -1528.
Leo Document ID = fd22d648-6b60-4d2c-ade1-38a575f42ba1
Approver: 
Approval Date & Time: 23-Jan-2018 03:00:15 GMT
Signature meaning: Approved
Approver: 
Approval Date & Time: 23-Jan-2018 14:08:22 GMT
Signature meaning: Approved
PPD
PPD